Emergent BioSolutions Inc
(NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, whic...

Website: http://www.emergentbiosolutions.com

Founded: 1998

Full Time Employees: 1,834

CEO: Robert G. Kramer Sr.

Sector: Healthcare

Industry: Drug Manufacturers-Specialty & Generic

Pharmaceuticals Nasal Spray Monkeypox Vaccine

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-08-03	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31

revenues:
product and services sales	149,700,000	143,800,000	222,000,000	130,300,000	209,100,000
contracts and grants	6,400,000	4,900,000	9,100,000	10,600,000	13,100,000	10,000,000	6,600,000	8,000,000	6,700,000	6,500,000	6,600,000	6,500,000	7,100,000	17,400,000	7,300,000	9,600,000	70,600,000	16,900,000	25,400,000	21,300,000	43,000,000	25,900,000	23,600,000	22,600,000	24,100,000	35,600,000	41,000,000	21,700,000	26,411,000	18,212,000	16,512,000	15,865,000	15,933,000	16,226,000	21,002,000	17,261,000	47,487,000	31,504,000								22,869,000	15,391,000	65,966,614	12,805	16,840,000	12,741,000	12,581,000	17,218,000	15,954,000	26,278,000	15,099,000	16,662,000	16,662,000	12,936,000	13,857,000	6,720,000	6,266,000	7,947,000	6,644,000	4,268,000	3,861,000	2,841,000	5,934,000	1,121,000	1,159,000	1,216,000	9,588,000	1,858,000	668,000	1,002,000
total revenues	156,100,000	148,700,000	231,100,000	140,900,000	222,200,000	293,800,000	254,700,000	300,400,000	276,600,000	270,500,000	337,900,000	165,100,000	330,700,000	240,000,000	242,700,000	307,500,000	723,200,000	329,000,000	397,500,000	343,000,000	583,000,000	385,200,000	394,700,000	192,500,000	360,300,000	311,800,000	243,200,000	190,600,000	270,733,000	173,653,000	220,200,000	117,814,000	193,809,000	149,434,000	100,772,000	116,858,000	151,663,000	142,914,000	101,487,000	111,002,000	168,104,000	164,940,000	126,112,000	63,633,000	137,954,000	110,325,000	53,884,000	281,673,362	89,102	82,436,000	43,100,000	66,592,000	70,379,000	50,311,000	107,948,000	58,762,000	88,141,000	88,141,000	18,533,000	103,247,000	73,986,000	62,138,000	46,800,000	53,804,000	43,272,000	73,191,000	64,519,000	35,750,000	56,599,000	43,485,000	42,720,000	89,637,000	43,644,000	23,186,000	26,448,000
yoy	-29.75%	-49.39%	-9.27%	-53.10%	-19.67%	8.61%	-24.62%	81.95%	-16.36%	12.71%	39.23%	-46.31%	-54.27%	-27.05%	-38.94%	-10.35%	24.05%	-14.59%	0.71%	78.18%	61.81%	23.54%	62.29%	1.00%	33.08%	79.55%	10.45%	61.78%	39.69%	16.21%	118.51%	0.82%	27.79%	4.56%	-0.70%	5.28%	-9.78%	-13.35%	-19.53%	74.44%	21.86%	49.50%	134.04%	-77.41%	154727.05%	33.83%	25.02%	322.98%	-99.87%	63.85%	-60.07%	13.32%	-20.15%	-42.92%	482.46%	-43.09%	19.13%	41.85%	-60.40%	91.89%	70.98%	-15.10%	-27.46%	50.50%	-23.55%	68.31%	51.03%	-60.12%	29.68%	87.55%	61.52%
qoq	4.98%	-35.66%	64.02%	-36.59%	-24.37%	15.35%	-15.21%	8.60%	2.26%	-19.95%	104.66%	-50.08%	37.79%	-1.11%	-21.07%	-57.48%	119.82%	-17.23%	15.89%	-41.17%	51.35%	-2.41%	105.04%	-46.57%	15.55%	28.21%	27.60%	-29.60%	55.90%	-21.14%	86.90%	-39.21%	29.70%	48.29%	-13.77%	-22.95%	6.12%	40.82%	-8.57%	-33.97%	1.92%	30.79%	98.19%	-53.87%	25.04%	104.75%	-80.87%	316024.62%	-99.89%	91.27%	-35.28%	-5.38%	39.89%	-53.39%	83.70%	-33.33%	0.00%	375.59%	-82.05%	39.55%	19.07%	32.77%	-13.02%	24.34%	-40.88%	13.44%	80.47%	-36.84%	30.16%	1.79%	-52.34%	105.38%	88.23%	-12.33%
operating expenses:
cost of product and services sales	72,000,000	84,900,000	85,900,000	66,900,000	88,500,000
research and development	10,500,000	12,100,000	13,500,000	12,500,000	15,100,000	13,800,000	32,700,000	15,100,000	29,400,000	15,300,000	26,000,000	40,600,000	57,600,000	39,200,000	49,800,000	46,400,000	83,000,000	49,600,000	48,900,000	52,500,000	43,750,000	84,400,000	47,900,000	42,700,000	62,800,000	53,400,000	63,900,000	46,100,000	51,998,000	37,006,000	24,745,000	29,051,000	28,498,000	22,659,000	25,751,000	20,476,000	27,117,000	27,188,000	35,347,000	34,154,000	32,486,000	41,868,000	40,941,000	38,702,000	44,207,000	37,401,000	30,256,000	120,136,061	28,937	30,278,000	30,724,000	27,390,000	30,645,000	26,246,000	29,376,000	29,216,000	31,481,000	31,481,000	34,759,000	29,615,000	21,156,000	18,602,000	19,922,000	19,226,000	18,772,000	20,680,000	15,910,000	14,162,000	16,627,000	17,206,000	11,475,000	12,269,000	12,777,000	13,342,000	15,570,000
selling, general and administrative	46,600,000	51,100,000	38,900,000	43,700,000	52,400,000	76,600,000	85,900,000	84,700,000	89,700,000	86,000,000	91,400,000	100,500,000	94,200,000	80,200,000	81,100,000	84,800,000	94,200,000	82,100,000	91,200,000	80,900,000	55,300,000	75,500,000	76,000,000	69,700,000	50,325,000	65,000,000	70,800,000	65,400,000	30,453,750	42,105,000	39,506,000	40,204,000	25,380,250	34,503,000	31,868,000	35,150,000	27,082,000	40,688,000	44,148,000	39,784,000	25,625,500	31,556,000	36,453,000	34,493,000	30,292,000	30,555,000	30,089,000	75,955,516	21,955	20,501,000	20,028,000	19,155,000	17,895,000	19,492,000	18,254,000	17,432,000	20,384,000	20,384,000	18,212,000	21,671,000	20,693,000	17,649,000	16,192,000	18,671,000	19,767,000	19,373,000	15,975,000	13,864,000	14,115,000	15,039,000	12,060,000	16,666,000	15,038,000	12,659,000	11,193,000
amortization of intangible assets	16,500,000	16,300,000	16,300,000	16,200,000	16,300,000	16,300,000	16,300,000	16,200,000	16,200,000	16,300,000	16,100,000	17,000,000	17,900,000	14,000,000	14,000,000	14,000,000	14,000,000	14,500,000	15,100,000	14,900,000	11,200,000	15,000,000	15,000,000	14,800,000	14,800,000	14,700,000		14,500,000
total operating expenses	145,600,000	176,600,000	154,600,000	139,300,000	172,300,000	229,300,000	458,200,000	260,600,000	320,400,000	512,600,000	630,800,000	313,200,000	395,800,000	282,000,000	314,700,000	301,100,000	445,800,000	363,700,000	383,000,000	247,600,000	324,900,000	323,900,000	268,700,000	204,100,000	282,600,000	241,100,000	250,200,000	217,800,000
income from operations	10,500,000	-27,900,000	76,500,000	1,600,000	49,900,000	64,500,000	-203,500,000	39,800,000	-43,800,000	-242,100,000	-292,900,000	-148,100,000	-65,100,000	-42,000,000	-72,000,000	6,400,000	277,400,000	-34,700,000	14,500,000	95,400,000	258,100,000	61,300,000	126,000,000	-11,600,000	77,700,000	70,700,000	-7,000,000	-27,200,000	11,199,000	21,310,000	66,776,000	-9,485,000	53,077,000	47,769,000	8,529,000	14,910,000	50,929,000	35,478,000	-13,620,000	8,561,000	49,892,000	53,005,000	21,452,000	-28,310,000	31,032,000	7,862,000	-25,458,000	29,947,491	18,147	14,712,000	-13,350,000	9,817,000	8,653,000	-12,538,000	45,990,000	1,408,000	20,207,000	20,207,000	-35,506,000	34,963,000	20,605,000	14,811,000	3,178,000	4,125,000	-3,951,000	22,710,000	17,266,000	854,000	15,338,000	2,558,000	11,175,000	43,158,000	4,422,000	-8,657,000	-5,831,000
yoy	-78.96%	-143.26%	-137.59%	-95.98%	-213.93%	-126.64%	-30.52%	-126.87%	-32.72%	476.43%	306.81%	-2414.06%	-123.47%	21.04%	-596.55%	-93.29%	7.48%	-156.61%	-88.49%	-922.41%	232.18%	-13.30%	-1900.00%	-57.35%	593.81%	231.77%	-110.48%	186.77%	-78.90%	-55.39%	682.93%	-163.62%	4.22%	34.64%	-162.62%	74.16%	2.08%	-33.07%	-163.49%	-130.24%	60.78%	574.19%	-184.26%	-194.53%	170903.47%	-46.56%	90.70%	205.06%	-99.79%	-217.34%	-129.03%	597.23%	-57.18%	-162.05%	-229.53%	-95.97%	-1.93%	36.43%	-1217.24%	747.59%	-621.51%	-34.78%	-81.59%	383.02%	-125.76%	787.80%	54.51%	-98.02%	246.86%	-129.55%	-291.65%
qoq	-137.63%	-136.47%	4681.25%	-96.79%	-22.64%	-131.70%	-611.31%	-190.87%	-81.91%	-17.34%	97.77%	127.50%	55.00%	-41.67%	-1225.00%	-97.69%	-899.42%	-339.31%	-84.80%	-63.04%	321.04%	-51.35%	-1186.21%	-114.93%	9.90%	-1110.00%	-74.26%	-342.88%	-47.45%	-68.09%	-804.02%	-117.87%	11.11%	460.08%	-42.80%	-70.72%	43.55%	-360.48%	-259.09%	-82.84%	-5.87%	147.09%	-175.78%	-191.23%	294.71%	-130.88%	-185.01%	164927.23%	-99.88%	-210.20%	-235.99%	13.45%	-169.01%	-127.26%	3166.34%	-93.03%	0.00%	-156.91%	-201.55%	69.68%	39.12%	366.05%	-22.96%	-204.40%	-117.40%	31.53%	1921.78%	-94.43%	499.61%	-77.11%	-74.11%	875.98%	-151.08%	48.47%
operating margin %	6.73%	-18.76%	33.10%	1.14%	22.46%	21.95%	-79.90%	13.25%	-15.84%	-89.50%	-86.68%	-89.70%	-19.69%	-17.50%	-29.67%	2.08%	38.36%	-10.55%	3.65%	27.81%	44.27%	15.91%	31.92%	-6.03%	21.57%	22.67%	-2.88%	-14.27%	4.14%	12.27%	30.33%	-8.05%	27.39%	31.97%	8.46%	12.76%	33.58%	24.82%	-13.42%	7.71%	29.68%	32.14%	17.01%	-44.49%	22.49%	7.13%	-47.25%	10.63%	20.37%	17.85%	-30.97%	14.74%	12.29%	-24.92%	42.60%	2.40%	22.93%	22.93%	-191.58%	33.86%	27.85%	23.84%	6.79%	7.67%	-9.13%	31.03%	26.76%	2.39%	27.10%	5.88%	26.16%	48.15%	10.13%	-37.34%	-22.05%
other income:
interest expense	-11,000,000	-14,700,000	-15,200,000	-14,700,000	-14,700,000	-8,300,000	-23,600,000	-24,300,000	-21,700,000	-19,700,000	-28,600,000	-17,900,000	-12,800,000	-8,500,000	-7,800,000	-8,200,000	-9,000,000	-8,400,000	-8,600,000	-8,500,000	-5,650,000	-7,600,000	-6,400,000	-8,600,000	-9,100,000	-10,300,000	-9,500,000	-9,600,000	-8,016,000	-642,000	-1,008,000	-234,000	-856,000	-1,991,000	-1,805,000	-1,938,000	-2,535,000	-2,049,000	-1,509,000	-1,524,000	-1,600,000	-1,635,000	-1,628,000	-1,661,000	-1,810,000	-1,721,000	-3,535,000	-5,986		-3,000	-11,000			-3,000			-6,000	-6,000				-2,000	-5,000	7,000	-4,000				2,000			-17,000		-21,000	-26,000
loss on assets held for sale					-12,200,000
other	13,900,000	-8,100,000	-3,700,000	-3,700,000	69,700,000	21,900,000	-2,700,000	-3,400,000	11,000,000	-3,400,000	-3,600,000	4,900,000	6,700,000	-13,400,000	-3,000,000	-2,000,000	-900,000	-2,400,000	1,300,000	-1,700,000	325,000	1,300,000	1,100,000
total other income	2,900,000	-22,800,000	-18,900,000	-18,400,000	42,800,000	77,900,000	-66,300,000	-27,700,000	-10,700,000	-23,800,000	42,700,000	-13,000,000	-6,100,000	-21,900,000	-10,800,000	-10,200,000	-9,900,000	-10,800,000	-7,300,000	-10,200,000	-5,325,000	-6,300,000	-5,300,000		-6,200,000	-11,800,000		-10,600,000	-7,656,000	249,000		62,000												-1,479,000	-1,331,000	-368,000	-2,983,000	2,097,800	146	25,000	29,000	39,000	936,000	876,000	-228,000	59,000	-21,000	-21,000	34,000	19,000	-965,000	380,000	375,000	372,000	428,000	289,000	272,000	309,000	477,000	650,000	650,000	839,000	451,000	579,000	1,025,000
income before income taxes	13,400,000	-50,700,000	57,600,000	-16,800,000	92,700,000	142,400,000	-269,800,000	12,100,000	-54,500,000	-265,900,000	-250,200,000	-161,100,000	-71,200,000	-63,900,000	-82,800,000	-3,800,000	267,500,000	-45,500,000	7,200,000	85,200,000					1,475,000	58,900,000	-15,100,000
income tax provision	6,600,000	3,900,000	6,400,000	-4,800,000	24,700,000		13,300,000	3,100,000	-5,000,000	-2,500,000	11,100,000	21,900,000									8,675,000	15,500,000	28,000,000
net income	6,800,000	-54,600,000	51,200,000	-12,000,000	68,000,000	114,800,000	-283,100,000	9,000,000	-49,500,000	-263,400,000	-261,300,000	-183,000,000	-88,000,000	-75,700,000	-56,400,000	-3,700,000	189,300,000	-32,700,000	4,600,000	69,700,000	185,400,000	39,500,000	92,700,000	-12,500,000	46,900,000	43,200,000	-9,500,000	-26,000,000	-3,481,000	20,945,000	50,144,000	-4,908,000	33,942,000	33,551,000	4,616,000	10,485,000	37,392,000	21,340,000	-10,947,000	3,991,000	33,347,000	36,942,000	14,100,000	-21,520,000	21,832,000	5,029,000	-20,236,000	18,127,958	13,491	10,356,000	-8,805,000	5,620,000	5,546,000	-8,022,000	26,900,000	-137,000	12,523,000	12,523,000	-23,173,000	23,888,000	11,944,000	9,434,000	1,918,000	3,661,000	-539,000	13,251,000	10,172,000	1,455,000	10,386,000	1,815,000	7,024,000	27,741,000	2,845,000	-4,961,000	-2,690,000
yoy	-90.00%	-147.56%	-118.09%	-233.33%	-237.37%	-143.58%	8.34%	-104.92%	-43.75%	247.95%	363.30%	4845.95%	-146.49%	131.50%	-1326.09%	-105.31%	2.10%	-182.78%	-95.04%	-657.60%	295.31%	-8.56%	-1075.79%	-51.92%	-1447.31%	106.25%	-118.95%	429.75%	-110.26%	-37.57%	986.31%	-146.81%	-9.23%	57.22%	-142.17%	162.72%	12.13%	-42.23%	-177.64%	-118.55%	52.74%	634.58%	-169.68%	-218.71%	161726.40%	-51.44%	129.82%	222.56%	-99.76%	-229.09%	-132.73%	-4202.19%	-55.71%	-164.06%	-216.08%	-100.57%	4.85%	32.74%	-1308.19%	552.50%	-2315.96%	-28.81%	-81.14%	151.62%	-105.19%	630.08%	44.82%	-94.76%	265.06%	-136.59%	-361.12%
qoq	-112.45%	-206.64%	-526.67%	-117.65%	-40.77%	-140.55%	-3245.56%	-118.18%	-81.21%	0.80%	42.79%	107.95%	16.25%	34.22%	1424.32%	-101.95%	-678.90%	-810.87%	-93.40%	-62.41%	369.37%	-57.39%	-841.60%	-126.65%	8.56%	-554.74%	-63.46%	646.91%	-116.62%	-58.23%	-1121.68%	-114.46%	1.17%	626.84%	-55.98%	-71.96%	75.22%	-294.94%	-374.29%	-88.03%	-9.73%	162.00%	-165.52%	-198.57%	334.12%	-124.85%	-211.63%	134270.75%	-99.87%	-217.61%	-256.67%	1.33%	-169.13%	-129.82%	-19735.04%	-101.09%	0.00%	-154.04%	-197.01%	100.00%	26.61%	391.87%	-47.61%	-779.22%	-104.07%	30.27%	599.11%	-85.99%	472.23%	-74.16%	-74.68%	875.08%	-157.35%	84.42%
net income margin %	4.36%	-36.72%	22.15%	-8.52%	30.60%	39.07%	-111.15%	3.00%	-17.90%	-97.38%	-77.33%	-110.84%	-26.61%	-31.54%	-23.24%	-1.20%	26.18%	-9.94%	1.16%	20.32%	31.80%	10.25%	23.49%	-6.49%	13.02%	13.86%	-3.91%	-13.64%	-1.29%	12.06%	22.77%	-4.17%	17.51%	22.45%	4.58%	8.97%	24.65%	14.93%	-10.79%	3.60%	19.84%	22.40%	11.18%	-33.82%	15.83%	4.56%	-37.55%	6.44%	15.14%	12.56%	-20.43%	8.44%	7.88%	-15.94%	24.92%	-0.23%	14.21%	14.21%	-125.04%	23.14%	16.14%	15.18%	4.10%	6.80%	-1.25%	18.10%	15.77%	4.07%	18.35%	4.17%	16.44%	30.95%	6.52%	-21.40%	-10.17%
earnings per common share
basic	130,000	-1,010,000	960,000	-220,000	1,250,000	2,160,000
diluted	70,000	-960,000	910,000	-220,000	1,190,000	2,060,000
weighted-average shares outstanding
basic	51,900,000	53,500,000	53,200,000	54,200,000	54,400,000	53,100,000	52,600,000	52,200,000	51,200,000	51,800,000	50,700,000	50,200,000
diluted	56,500,000	56,700,000	56,500,000	54,200,000	57,300,000	55,600,000	52,600,000	52,200,000	51,200,000	51,800,000	50,700,000	50,200,000
exclusive of intangible asset amortization
impairment of long-lived assets							27,200,000				306,700,000
gain on sale of business and assets held for sale		-3,050,000					-40,000,000
commercial product sales						95,300,000	120,000,000	118,500,000
mcm product sales						174,200,000	63,400,000	155,400,000
total product sales						269,500,000	183,400,000	273,900,000
bioservices:
services						13,900,000	64,500,000	18,300,000	20,600,000	13,200,000	26,400,000	13,400,000	17,700,000	36,200,000	2,700,000	51,800,000	51,200,000	112,600,000
leases						400,000	200,000	200,000	200,000	1,000,000	2,700,000	1,800,000	200,000	200,000	-4,500,000	9,000,000	167,100,000	-71,000,000
total bioservices revenues						14,300,000	64,700,000	18,500,000
cost of commercial product sales						47,200,000	53,400,000	52,100,000
cost of mcm product sales						54,000,000	31,100,000	62,200,000
cost of bioservices						21,400,000	211,600,000	30,300,000
goodwill impairment										218,200,000
gain on sale of business						64,300,000				-700,000	74,900,000
income tax benefit						27,600,000							3,675,000	-11,800,000										8,800,000				-11,800,000
net loss per common share
basic							-5,380,000		-3,492,500	-5,080,000	-5,150,000													-240,000				-510,000
diluted							-5,380,000		-3,492,500	-5,080,000	-5,150,000													-240,000				-510,000
net income per common share
basic								170,000					-1,760,000	-1,520,000	-1,130,000	-70,000	3,540,000	-610,000	90,000	1,310,000	570,000	750,000	1,760,000		37,500	840,000	-180,000
diluted								170,000					-1,760,000	-1,520,000	-1,130,000	-70,000	3,500,000	-610,000	90,000	1,280,000	557,500	730,000	1,730,000		37,500	830,000	-180,000
product sales									173,850,000	249,800,000	302,200,000	143,400,000	305,700,000	186,200,000	237,200,000	237,100,000	434,300,000	270,500,000	181,200,000	137,900,000	340,900,000	202,200,000	298,500,000	148,200,000	310,800,000	256,200,000	183,500,000	153,000,000	217,385,000	133,269,000	180,075,000	75,771,000	161,641,000	114,296,000	63,610,000	81,969,000	87,493,000	96,698,000	58,546,000	71,706,000	132,649,000	123,953,000	82,023,000	18,291,000	84,457,000	78,269,000	35,767,000	215,706,748	76,297	65,596,000	30,359,000	54,011,000	53,161,000	34,357,000	81,670,000	43,663,000	71,479,000	71,479,000	5,597,000	89,390,000	67,266,000	55,872,000	38,853,000	47,160,000	39,004,000	69,330,000	61,678,000	29,816,000	55,478,000	42,326,000	41,504,000	80,049,000	41,786,000	22,518,000	25,446,000
contract development and manufacturing
total cdmo revenues									14,425,000	14,200,000	29,100,000	15,200,000
cost of product sales									92,150,000	132,500,000	134,900,000	102,900,000	167,300,000	85,500,000	91,000,000	80,300,000	145,000,000	103,200,000																														46,034,294	20,063	16,945,000	5,698,000	10,230,000	13,186,000	7,511,000	14,328,000	10,706,000	16,069,000	16,069,000	1,068,000	16,998,000	11,532,000	11,076,000	7,508,000	11,782,000	8,684,000	10,428,000	15,368,000	6,870,000	10,519,000	8,682,000	8,010,000	17,544,000	11,407,000	5,842,000	5,516,000
cost of cdmo									37,925,000	44,300,000	55,700,000	52,200,000	52,100,000	63,100,000
cdmo:
loss per common share
basic												-3,650,000
diluted												-3,650,000
total cdmo													17,900,000	36,400,000
shares used in computing net loss per common share
basic													-100,000	49,900,000	50,000,000	50,700,000	-0.1	53.7	53.6	53.3	13.125	53	52.6	52	12.85	51.6	51.5	51.2
diluted													-100,000	49,900,000	50,000,000	50,700,000	-0.2	53.7	54	54.5	13.4	54.3	53.5	52	13.075	52.3	51.5	51.2
contract development and manufacturing:
total contract development and manufacturing															-1,800,000	60,800,000	104,075,000	41,600,000
cost of contract development and manufacturing															78,800,000	75,600,000	76,900,000	114,300,000
income taxes															26,400,000	100,000	88,800,000	12,800,000	-2,600,000	-15,500,000
shares used in computing net income per common share
basic													-100,000	49,900,000	50,000,000	50,700,000	-0.1	53.7	53.6	53.3	13.125	53	52.6	52	12.85	51.6	51.5	51.2
diluted													-100,000	49,900,000	50,000,000	50,700,000	-0.2	53.7	54	54.5	13.4	54.3	53.5	52	13.075	52.3	51.5	51.2
shares used in computing income per share
basic													-100,000	49,900,000	50,000,000	50,700,000	-0.1	53.7	53.6	53.3	13.125	53	52.6	52	12.85	51.6	51.5	51.2
diluted													-100,000	49,900,000	50,000,000	50,700,000	-0.2	53.7	54	54.5	13.4	54.3	53.5	52	13.075	52.3	51.5	51.2
contract development and manufacturing services																			190,900,000	183,800,000	199,100,000	157,100,000	72,600,000	21,700,000
cost of product sales and contract development and manufacturing services																			227,800,000	99,300,000	88,925,000	149,000,000	129,800,000	76,900,000
income before provision for income taxes																					38,600,000	55,000,000	120,700,000	-21,300,000					19,489,250	21,559,000	65,821,000	-9,423,000							-14,892,000	7,339,000	47,881,000	52,076,000	19,600,000
other expense																								-1,100,000							-253,000		-96,750	-101,000
total other expense																								-9,700,000			-8,100,000				-955,000		-1,132,000	-1,455,000	-1,808,000	-1,265,000	-1,123,500	-1,925,000	-1,272,000	-1,222,000	-1,064,750	-929,000	-1,852,000
shares used in computing loss per share
basic													-100,000	49,900,000	50,000,000	50,700,000	-0.1	53.7	53.6	53.3	13.125	53	52.6	52	12.85	51.6	51.5	51.2
diluted													-100,000	49,900,000	50,000,000	50,700,000	-0.2	53.7	54	54.5	13.4	54.3	53.5	52	13.075	52.3	51.5	51.2
contract manufacturing																									13,650,000	20,000,000	18,700,000	15,900,000	26,937,000	22,172,000	23,613,000	26,178,000	16,235,000	18,912,000	16,160,000	17,628,000	16,683,000	14,712,000	10,156,000	7,587,000	10,525,000	11,341,000	8,859,000	12,243,000	9,433,000	9,187,000	2,726,000
cost of product sales and contract manufacturing																									75,175,000	108,000,000	100,800,000	91,800,000	101,851,000	73,232,000	89,173,000	58,044,000	70,258,000	44,503,000	34,624,000	46,322,000	38,259,000	39,560,000	35,612,000	28,503,000	39,770,000	38,511,000	27,266,000	18,748,000	32,423,000	34,507,000	18,997,000
other income																									2,900,000	-1,500,000	1,400,000	-1,000,000	1,589,000	190,000		74,000			-586,000	300,000	439,000	-234,000	17,000	116,000	-524,000	602,000	-497,000	100,000	420,000	1,322,000	512,000	1,969,907	58	18,000	17,000	-16,000	907,000	854,000	-252,000	37,000	-39,000	-39,000	-1,000	-11,000	-1,003,000	6,000	-8,000	-22,000	6,000	-10,000	-24,000	-49,000		198,000	-14,000	-8,000	-14,000	1,000	177,000
income tax expense																									-425,000	15,700,000	-5,600,000
amortization of acquisition-related intangible assets																											14,700,000
loss before benefit from income taxes																												-37,800,000																										-11,662,000																					-4,806,000
interest income																													307,250	701,000	306,000	222,000	160,000	637,000	583,000	373,000	289,000	358,000	220,000	186,000	113,000	104,000	273,000	82,000	59,000	31,000	40,000	133,879	88	10,000	23,000	55,000	29,000	25,000	24,000	22,000	24,000	24,000	35,000	30,000	38,000	376,000	388,000	387,000	426,000	305,000	300,000	401,000	476,000	457,000	665,000	864,000	472,000	599,000	874,000
provision for income taxes																													7,024,000	614,000	15,677,000	-4,515,000	18,011,000	12,763,000	2,105,000	3,160,000	16,836,000	13,165,000	-3,945,000	3,348,000	14,534,000	15,134,000	5,500,000
net income per share																													-0.08	0.42	1	-0.1	0.79	0.81	0.11	0.26	1.21	0.52	-0.27	0.1	0.193	0.95
weighted-average number of shares - basic																														50,071,632	49,896,124	49,580,089		41,222,504	41,013,764	40,727,755		40,465,423	40,202,821	39,542,656		38,831,341	38,480,754	37,949,358	37,507,220	37,416,554	36,854,370	36,080,495		36,144,063	35,968,064	36,202,801	36,182,826	36,045,839	35,658,907	35,855,217	35,619,514	35,619,514	35,179,317	31,782,286	31,301,796	31,097,445	30,879,970	30,444,485		30,271,317	30,184,098	29,835,134	29,818,994	29,763,872	29,750,237	28,995,667	29,739,797	28,599,405	27,864,328
weighted-average number of shares - diluted																														51,486,996	51,162,909	49,580,089		50,467,829	50,078,594	49,718,426		49,440,313	40,202,821	48,359,892		47,784,550	47,410,413	37,949,358	46,557,163	38,333,425	36,854,370	36,420,662		36,527,014	35,968,064	36,670,094	36,556,697	36,045,839	36,206,052	36,447,933	36,667,452	36,667,452	35,179,317	32,539,500	32,113,313	31,900,000	31,432,751	31,375,305		30,949,612	31,454,456	30,458,098	30,590,950	30,044,691	29,819,727	29,663,127	29,900,571	28,599,405	27,864,328
income from continuing operations before provision for income taxes																																	51,953,000	46,314,000	6,721,000	13,645,000	49,122,000	33,553,000
net income from continuing operations																																	33,942,000	33,551,000	4,616,000	10,485,000	32,286,000	20,388,000
net income from discontinued operations
net loss from discontinued operations
net income from continuing operations - basic																																				260
net loss from discontinued operations - basic
net income from continuing operations - diluted																																				0.23
net loss from discontinued operations - diluted
income from discontinued operations																																					-3,963,500	952,000
income from continuing operations																																					0.188	0.5
contracts, grants and collaborations																																							32,785,000	31,709,000	24,930,000	29,646,000	35,230,000	33,099,000	44,064,000
operating expense:
income per share - basic																																											0.37		0.58	0.13				0.29		0.18	0.21
income per share - diluted																																											0.32		0.49	0.13				0.29		0.18	0.21
income before benefit from income taxes																																												-29,789,000	29,701,000	7,494,000	-28,441,000	32,045,291	18,293	14,737,000	-13,321,000	9,856,000	9,589,000		45,762,000	1,467,000	20,186,000	20,186,000	-35,472,000	34,982,000	19,640,000	15,191,000	3,553,000	4,497,000	-3,523,000	22,999,000	17,538,000			3,208,000	11,825,000	43,997,000	4,873,000	-8,078,000
benefit from income taxes																																												-8,269,000	7,869,000	2,465,000	-8,205,000	13,917,333	4,802	4,381,000	-4,516,000	4,236,000	4,043,000	-3,640,000	18,862,000	1,604,000	7,663,000	7,663,000	-12,299,000	11,094,000	7,696,000	5,757,000	1,635,000	836,000	-2,984,000	9,748,000	7,366,000	4,000	5,857,000	1,393,000	4,801,000	16,256,000	2,028,000	-3,117,000	-2,116,000
loss per share - basic																																															-0.55				-0.22			-0.19
loss per share - diluted																																												-0.57			-0.55				-0.22			-0.19
net income attributable to noncontrolling interest																																																5,380,129		128,000	743,000	997,000	2,086,000							2,359,000	1,176,000	374,000	605,000	573,000	1,488,000	1,591,000	947,000
net income attributable to emergent biosolutions inc.																																													21,832,000	5,029,000	-20,236,000	23,508,087	13,491	10,484,000	-8,062,000	6,617,000	7,632,000		28,657,000	1,549,000	14,210,000	14,210,000	-21,397,000	26,247,000	13,120,000	9,808,000	2,523,000	4,234,000	949,000	14,842,000	11,119,000
impairment of in-process research and development																																																						9,600,000
income per share – basic																																																0.11	0.37
income per share – diluted																																																0.11	0.36
weighted-average number of shares – basic																																																	36,272,579
weighted-average number of shares – diluted																																																	37,015,529
net loss attributable to noncontrolling interest																																																						1,193,000
net loss attributable to emergent biosolutions inc.																																																						-6,829,000
net income attributable to noncontrolling interests																																																							1,287,250	1,686,000	1,687,000	1,687,000	1,776,000
earnings per share - basic																																																							0.81	0.04	0.4	0.4	-0.61	0.81	0.42	0.32	0.08			0.49	0.37	0.04	0.35	0.06	0.24	0.96	0.1	-0.17	-0.1
earnings per share - diluted																																																							0.8	0.04	0.39	0.39	-0.61	0.79	0.41	0.31	0.08			0.48	0.35	0.04	0.34	0.06	0.24	0.94	0.1	-0.17	-0.1
earnings per share — basic																																																																0.223	0.03
earnings per share — diluted																																																																0.215	0.03
weighted-average number of shares — basic																					52.7				51.5				50.1				41,816,431				40,184,159				38,595,435																								30,506,661
weighted-average number of shares — diluted																					53.8				52.4				51.4				50,327,937				49,335,112				47,255,842																								31,534,831
minority interest in subsidiary																																																																				296,000	428,000
income before benefit from
(benefit from) income taxes																																																																				7,819,500	16,243,000
purchased in-process research and development

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2003-12-31

assets
current assets:
cash and cash equivalents	160,300,000	205,400,000	245,500,000	267,300,000	149,100,000	149,900,000	69,700,000	78,500,000	111,700,000	87,800,000	88,600,000	430,200,000	642,600,000	240,900,000	358,100,000	435,800,000	576,100,000	403,800,000	447,500,000	547,800,000	621,300,000	415,000,000	268,800,000	181,500,000	167,800,000	139,200,000	177,400,000	137,200,000	112,200,000	339,358,000	190,237,000	163,606,000	178,292,000	340,991,000	315,627,000	270,170,000	271,513,000	298,932,000	333,395,000	341,016,000	312,795,000	308,718,000	214,841,000	216,515,000	242,249,000	168,130,000	160,215,000	179,338,000	172,561,000	156,243,000	130,238,000	197,901,000	161,843,000	150,425,000	143,901,000	125,346,000	122,094,000	136,925,000	169,019,000	151,229,000	102,193,000	116,384,000	102,924,000	118,777,000	102,508,000	61,380,000	91,473,000	104,688,000	84,007,000	92,747,000	105,730,000	24,266,000	33,980,000	67,645,000	7,119,000
restricted cash	1,200,000	3,700,000	3,700,000	3,700,000	3,700,000	6,500,000	1,300,000	500,000						100,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	1,043,000	1,043,000	1,043,000	1,043,000	1,043,000																					220,000	217,000	217,000	217,000	217,000	215,000	215,000	215,000	215,000	208,000	208,000	208,000	208,000	200,000	5,200,000	5,200,000	5,200,000	5,192,000
accounts receivable	121,600,000	84,200,000	149,500,000	79,800,000	203,700,000	121,300,000	196,300,000	233,500,000	191,000,000	216,500,000	290,100,000	155,900,000	158,400,000	191,300,000	175,000,000	181,800,000	274,700,000	254,600,000	261,900,000	184,400,000	230,900,000	196,100,000	258,600,000	162,500,000	270,700,000	281,200,000	218,100,000	121,500,000	262,500,000	76,955,000	189,489,000	122,090,000	143,653,000	129,357,000	102,511,000	128,082,000	138,478,000	69,633,000	66,749,000	69,560,000	120,767,000	57,037,000	99,718,000	64,059,000	44,111,000	78,270,000	62,938,000	60,587,000	30,093,000	54,369,000	62,964,000	17,085,000	46,815,000	43,652,000	74,153,000	48,994,000	47,263,000	11,976,000	39,326,000	7,937,000	45,765,000	33,405,000	54,872,000	25,713,000	55,399,000	74,136,000	24,855,000	14,070,000	22,451,000	21,518,000	18,817,000	42,013,000	19,397,000	3,935,000
inventories	327,600,000	343,400,000	356,300,000	338,600,000	314,000,000	322,700,000	317,500,000	333,400,000	328,900,000	354,100,000	354,300,000	367,900,000	351,800,000	546,300,000	425,500,000	400,700,000	350,800,000	364,600,000	386,400,000	406,500,000	307,000,000	270,100,000	236,200,000	248,100,000	222,500,000	230,200,000	232,000,000	211,000,000	205,800,000	125,745,000	139,373,000	155,196,000	142,812,000	68,889,000	70,529,000	70,732,000	74,002,000	81,160,000	96,674,000	88,200,000	76,936,000	80,070,000	84,708,000	82,134,000	62,533,000	66,030,000	71,268,000	14,643,000	16,325,000	18,582,000	22,148,000	18,245,000	16,008,000	17,319,000	14,661,000	17,979,000	17,262,000	22,163,000	12,722,000	17,320,000	17,116,000	17,081,000	13,521,000	15,816,000	14,042,000	14,152,000	19,728,000	17,516,000	18,879,000	18,790,000	16,897,000	25,623,000	28,885,000	26,885,000
prepaid expenses and other current assets	26,900,000	25,800,000	25,600,000	24,000,000	30,200,000	61,000,000	36,000,000	36,500,000	47,900,000	62,400,000	44,700,000	41,700,000	57,900,000	139,900,000	125,400,000	81,800,000	70,300,000	88,300,000	66,100,000	42,200,000	36,500,000	77,400,000	32,100,000	24,100,000	20,400,000	49,200,000	65,000,000	58,600,000	31,500,000	20,047,000	21,166,000	27,670,000	17,157,000	15,754,000	14,955,000	13,411,000	16,229,000	18,439,000	22,045,000	25,613,000	21,541,000	22,749,000	21,596,000	24,424,000	26,477,000	16,345,000	14,982,000	12,896,000	13,184,000	11,199,000	9,703,000	9,759,000	7,489,000	7,907,000	8,276,000	9,033,000	7,742,000	7,875,000	8,814,000	8,690,000	7,732,000	7,271,000	7,838,000	6,131,000	4,303,000	4,253,000	6,623,000	5,700,000	4,691,000	3,074,000	2,866,000	2,475,000	2,561,000	1,970,000
total current assets	637,600,000	662,500,000	786,900,000	719,500,000	706,800,000	661,400,000	654,500,000	682,400,000	679,500,000	720,800,000	777,700,000	1,221,300,000	1,210,700,000	1,118,500,000	1,084,200,000	1,100,300,000	1,272,100,000	1,111,500,000	1,162,100,000	1,181,100,000	1,195,900,000	958,800,000	795,900,000	626,600,000	686,200,000	700,000,000	692,700,000	528,500,000	620,800,000	563,148,000	541,308,000	476,649,000	485,389,000	556,034,000	509,741,000	489,166,000	510,218,000	479,995,000	528,047,000	528,160,000	538,612,000	473,490,000	435,488,000	405,811,000	383,632,000	345,449,000	327,203,000	273,115,000	234,015,000	248,159,000	237,079,000	252,935,000	243,215,000	239,542,000	254,418,000	236,765,000	223,844,000	216,203,000	243,493,000	210,836,000	194,446,000	191,536,000	193,814,000	195,417,000	203,722,000	163,921,000	152,679,000	151,974,000	140,028,000	139,629,000	144,310,000	107,363,000	99,610,000	103,690,000
property, plant and equipment	199,400,000	205,400,000	209,800,000	216,100,000	221,000,000	278,100,000	306,200,000	379,400,000	382,800,000	395,400,000	395,500,000	716,800,000	817,600,000	806,700,000	798,400,000	807,500,000	800,100,000	768,700,000	743,500,000	692,900,000	644,100,000	606,500,000	580,100,000	549,200,000	542,300,000	529,100,000	520,500,000	513,400,000	510,200,000	435,075,000	419,157,000	411,269,000	407,210,000	386,457,000	380,240,000	381,102,000	376,448,000	362,544,000	359,034,000	342,083,000	331,856,000	327,643,000	320,084,000	315,489,000	304,211,000	302,455,000	303,468,000	264,240,000	263,056,000	248,504,000	242,344,000	232,310,000	224,894,000	218,749,000	208,973,000	188,245,000	172,481,000	157,963,000	152,701,000	141,257,000	136,839,000	133,493,000	131,834,000	112,645,000	110,383,000	127,245,000	124,656,000	120,898,000	118,365,000	115,421,000	110,218,000	103,479,000	96,576,000	87,836,000
intangible assets	470,400,000	436,500,000	452,700,000	469,000,000	485,200,000	517,800,000	534,100,000	550,400,000	566,600,000	582,800,000	592,800,000	608,900,000	728,800,000	722,700,000	576,600,000	590,600,000	604,600,000	618,600,000	633,100,000	648,200,000	663,100,000	678,100,000	693,200,000	708,100,000	712,900,000	727,700,000	742,400,000	757,100,000	761,600,000	107,861,000	111,773,000	115,685,000	119,597,000	29,202,000	30,756,000	32,311,000	33,865,000	35,419,000	52,645,000	55,010,000	57,375,000	59,738,000	62,110,000	56,202,000	64,464,000	66,678,000	68,928,000	30,148,000	30,771,000
other assets	13,000,000	14,200,000	11,600,000	12,500,000	13,100,000	20,500,000	18,700,000	191,400,000	194,300,000	194,100,000	194,600,000	184,600,000	191,300,000	35,700,000	51,300,000	57,100,000	57,300,000	102,200,000	109,900,000	111,400,000	113,400,000	106,400,000	101,600,000	81,800,000	76,900,000	67,400,000	56,400,000	46,000,000	13,700,000	5,757,000	4,869,000	3,078,000	6,046,000	6,644,000	3,723,000	3,037,000	2,483,000	1,781,000	1,846,000	2,117,000	7,060,000	6,844,000	7,247,000	7,696,000	8,340,000	8,768,000	9,365,000	3,373,000	441,000	562,000	573,000	750,000	713,000	745,000	807,000	707,000	712,000	1,129,000	1,198,000	1,128,000	1,133,000	1,177,000	1,187,000	1,451,000	1,121,000	1,163,000	1,172,000	1,726,000	1,364,000	1,580,000	1,383,000	1,412,000	1,432,000	1,293,000
total assets	1,320,400,000	1,318,600,000	1,461,000,000	1,417,100,000	1,426,100,000	1,477,800,000	1,513,500,000	1,803,600,000	1,823,200,000	1,893,100,000	2,178,800,000	2,949,800,000	3,166,600,000	2,908,500,000	2,735,400,000	2,780,400,000	2,959,000,000	2,867,500,000	2,915,200,000	2,900,100,000	2,883,200,000	2,616,300,000	2,466,100,000	2,278,700,000	2,327,300,000	2,333,800,000	2,321,300,000	2,153,700,000	2,229,400,000	1,173,623,000	1,138,891,000	1,068,467,000	1,070,206,000	1,024,202,000	970,483,000	951,639,000	970,111,000	932,026,000	1,056,466,000	1,035,897,000	1,043,592,000	976,548,000	943,323,000	917,845,000	869,291,000	837,249,000	823,251,000	626,630,000	595,464,000	555,614,000	538,385,000	540,025,000	527,140,000	514,687,000	546,864,000	512,962,000	493,984,000	471,277,000	500,319,000	366,237,000	345,747,000	342,791,000	344,689,000	316,802,000	326,385,000	303,782,000	290,788,000	287,396,000	277,919,000	273,641,000	273,508,000	226,751,000	206,996,000	203,893,000	37,127,000
liabilities and stockholders' equity
current liabilities:
accounts payable	39,500,000	55,600,000	57,400,000	63,700,000	58,100,000	82,100,000	95,900,000	100,200,000	112,200,000	112,700,000	108,300,000	124,200,000	103,500,000	103,800,000	106,200,000	107,300,000	128,900,000	135,200,000	151,800,000	142,200,000	136,100,000	102,800,000	84,800,000	84,200,000	94,800,000	91,300,000	124,500,000	78,600,000	80,700,000	38,874,000	41,629,000	46,216,000	41,751,000	30,111,000	29,604,000	27,179,000	34,649,000	46,342,000	58,974,000	45,611,000	45,966,000	41,248,000	41,824,000	40,583,000	39,351,000	36,968,000	36,643,000	27,521,000	29,018,000	25,711,000	23,871,000	27,348,000	23,301,000	28,316,000	40,530,000	33,902,000	32,182,000	24,034,000	25,409,000	22,518,000	20,300,000	16,164,000	17,159,000	21,236,000	17,568,000	17,186,000	18,254,000	16,673,000	19,933,000	17,863,000	17,979,000	19,383,000	17,347,000	19,003,000
accrued expenses	9,400,000	12,200,000	13,900,000	13,600,000	13,200,000	16,100,000	17,200,000	14,300,000	18,600,000	17,000,000	31,200,000	21,300,000	34,900,000	35,900,000	40,300,000	29,300,000	51,700,000	42,900,000	33,800,000	25,000,000	46,900,000	34,900,000	33,800,000	41,500,000	39,500,000	51,800,000	54,800,000	49,600,000
accrued compensation	22,000,000	41,800,000	36,600,000	31,500,000	24,700,000	63,300,000	66,700,000	42,000,000	74,100,000	82,500,000	69,600,000	56,800,000	88,300,000	82,500,000	74,400,000	56,400,000	88,700,000	73,400,000	63,200,000	55,000,000	84,600,000	76,900,000	59,000,000	47,500,000	62,400,000	55,800,000	44,700,000	36,900,000	58,200,000	41,807,000	29,259,000	24,513,000	37,882,000	32,626,000	24,326,000	23,318,000	34,537,000	32,102,000	29,778,000	26,528,000	34,683,000	30,089,000	26,320,000	20,818,000	26,850,000	23,044,000	18,242,000	24,615,000	18,421,000	15,481,000	11,675,000	16,170,000	13,980,000	9,982,000	20,884,000	14,735,000	13,823,000	13,687,000	23,975,000	13,749,000	11,580,000	9,346,000	14,926,000	14,163,000	9,962,000	8,286,000	11,380,000	10,378,000	7,315,000	6,592,000	9,502,000	7,616,000	7,609,000	4,723,000
accrued acquisition obligation	50,400,000
deferred revenue	12,200,000																										77,000,000																					1,834,000	2,038,000	2,049,000	2,008,000	1,574,000	1,504,000	283,000						253,000	241,000	241,000	255,000	255,000	478,000
current tax liability	7,200,000	6,800,000
other current liabilities	8,000,000	15,800,000	24,100,000	13,600,000	11,100,000	67,600,000	14,600,000	14,500,000	32,700,000	38,200,000	28,900,000	25,200,000	45,900,000	25,000,000	24,200,000	24,600,000	72,900,000	82,300,000	100,200,000	122,000,000	83,100,000	53,800,000	32,000,000	7,600,000	3,500,000	10,600,000	12,500,000	10,500,000
total current liabilities	148,700,000	132,200,000	136,500,000	127,100,000	111,900,000	229,900,000	619,700,000	630,200,000	651,300,000	664,000,000	693,200,000	1,215,700,000	1,229,900,000	268,400,000	276,700,000	249,200,000	373,800,000	365,400,000	377,800,000	370,200,000	384,500,000	299,300,000	293,700,000	207,100,000	216,300,000	275,300,000	301,200,000	248,400,000	200,400,000	102,014,000	96,813,000	86,870,000	100,068,000	75,432,000	72,926,000	67,706,000	105,856,000	110,306,000	103,858,000	90,455,000	99,611,000	88,725,000	86,962,000	80,297,000	81,417,000	76,427,000	72,324,000	56,651,000	56,632,000	48,778,000	43,541,000	50,572,000	44,465,000	42,995,000	71,054,000	68,931,000	72,504,000	70,934,000	75,719,000	49,858,000	45,444,000	48,123,000	54,701,000	57,307,000	72,910,000	54,206,000	54,021,000	51,568,000	52,370,000	49,381,000	55,661,000	35,511,000	32,261,000	30,465,000
debt	573,600,000	572,100,000	663,100,000	667,800,000	665,700,000																					813,300,000	830,400,000
deferred tax liability	33,300,000	37,800,000	36,300,000	46,500,000	60,400,000	41,900,000	34,800,000	34,800,000	47,200,000	52,400,000	57,900,000	59,700,000	71,800,000	113,800,000	93,400,000	94,800,000	94,900,000	53,000,000	53,200,000	53,300,000	53,200,000	64,000,000	63,900,000	63,900,000	63,900,000	61,100,000	65,600,000	66,400,000	67,500,000																			88,000																								243,000	195,000	104,000
other liabilities	41,700,000	53,900,000	42,600,000	39,500,000	35,400,000	35,800,000	25,700,000	28,000,000	28,900,000	31,300,000	23,400,000	24,100,000	33,400,000	44,900,000	58,500,000	49,300,000	52,700,000	58,700,000	61,400,000	62,900,000	67,800,000	57,400,000	59,400,000	58,900,000	48,600,000	53,000,000	47,800,000	44,300,000	38,000,000	4,619,000	4,656,000	4,850,000	4,675,000	1,702,000	1,670,000	1,632,000	1,604,000	1,440,000	1,553,000	1,337,000	1,328,000	1,253,000	1,232,000	1,270,000	1,176,000	1,230,000	1,500,000	2,117,000	1,768,000	1,685,000	1,852,000	2,175,000	2,013,000	2,005,000	1,984,000	1,882,000	2,017,000	1,940,000	1,882,000	1,160,000	1,350,000	1,387,000	1,246,000	1,613,000	1,823,000	1,587,000	1,483,000	1,495,000	1,649,000	1,636,000	1,627,000	1,574,000	1,922,000	1,802,000
total liabilities	797,300,000	796,000,000	878,500,000	880,900,000	873,400,000	969,400,000	1,127,200,000	1,139,700,000	1,173,900,000	1,195,900,000	1,222,500,000	1,747,200,000	1,783,600,000	1,459,200,000	1,222,200,000	1,205,100,000	1,340,000,000	1,344,800,000	1,371,500,000	1,377,300,000	1,436,200,000	1,364,800,000	1,267,300,000	1,203,900,000	1,238,800,000	1,298,800,000	1,332,400,000	1,166,200,000	1,218,500,000	206,974,000	200,545,000	187,187,000	157,861,000	360,492,000	349,884,000	341,220,000	373,906,000	384,403,000	383,794,000	368,915,000	383,575,000	371,236,000	381,072,000	379,967,000	356,153,000	349,482,000	345,756,000	137,465,000	128,607,000	106,532,000	102,580,000	111,613,000	104,618,000	102,592,000	130,137,000	128,459,000	112,754,000	112,354,000	126,758,000	87,243,000	83,704,000	93,675,000	100,874,000	79,420,000	95,983,000	91,001,000	91,439,000	94,567,000	96,804,000	95,044,000	102,349,000	83,258,000	66,976,000	65,872,000
stockholders' equity:
preferred stock, 0.001 par value per share...
common stock, 0.001 par value per share...	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000
treasury stock	-261,600,000	-252,600,000	-243,500,000	-234,600,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-227,700,000	-204,400,000	-152,200,000	-39,600,000	-39,600,000	-39,600,000	-39,600,000	-39,600,000	-39,600,000	-39,600,000	-39,600,000	-39,700,000	-39,700,000	-39,600,000	-39,600,000	-39,642,000	-39,642,000	-39,642,000	-39,497,000	-6,503,000	-6,503,000	-6,501,000	-6,420,000	-6,420,000	-6,420,000	-6,420,000	-6,420,000	-6,320,000	-6,320,000	-6,320,000	-6,119,000	-6,119,000	-6,119,000	-6,119,000	-5,906,000	-5,906,000	-5,906,000	-1,457,000
additional paid-in capital	944,500,000	942,400,000	938,600,000	935,200,000	930,800,000	924,400,000	915,300,000	909,800,000	904,400,000	899,700,000	895,800,000	878,200,000	873,500,000	860,100,000	849,200,000	834,800,000	829,400,000	816,800,000	804,400,000	790,100,000	784,900,000	770,900,000	758,500,000	726,200,000	716,100,000	708,800,000	701,800,000	690,200,000	688,600,000	640,178,000	632,569,000	624,484,000	618,416,000	370,855,000	360,999,000	355,661,000	352,435,000	342,888,000	337,947,000	322,384,000	317,971,000	297,953,000	291,339,000	280,653,000	264,877,000	260,778,000	255,675,000	247,637,000	240,372,000	236,099,000	232,887,000	228,080,000	225,231,000	222,746,000	220,654,000	215,938,000	213,320,000	204,367,000	197,689,000	130,832,000	127,349,000	123,643,000	120,492,000	118,563,000	113,066,000	110,877,000	109,170,000	104,288,000	103,134,000	102,163,000	101,933,000	101,992,000	101,203,000	93,936,000
accumulated other comprehensive loss	-6,900,000	-7,500,000	-7,500,000	-8,100,000	-6,100,000	-7,300,000	-5,500,000	-5,500,000						-5,200,000	-6,100,000	-9,300,000	-16,100,000	-23,100,000	-22,400,000	-24,400,000	-25,300,000	-21,400,000	-22,200,000	-21,200,000	-9,900,000	-9,100,000	-5,000,000	-4,500,000	-5,500,000	-4,666,000	-4,415,000	-3,251,000	-3,698,000	-3,815,000	-3,519,000	-3,747,000	-4,331,000	-3,572,000	-3,080,000	-4,152,000	-2,713,000	-4,152,000	-3,657,000	-3,242,000	-3,810,000	-3,251,000	-3,391,000	-3,465,000	-3,502,000	-3,513,000	-3,759,000	-3,901,000	-3,249,000	-3,229,000	-3,313,000	-2,894,000	-2,771,000	-2,803,000	-2,110,000	-2,173,000	-1,641,000	-1,261,000	-1,476,000	-1,130,000	-1,214,000	-939,000	-859,000	-1,040,000	-1,215,000	-946,000	-1,130,000	-1,117,000	-954,000	-643,000
accumulated deficit	-153,000,000	-159,800,000	-105,200,000	-156,400,000	-144,400,000	-181,100,000	-295,900,000	-12,800,000
total stockholders’ equity	523,100,000	522,600,000	582,500,000	536,200,000	552,700,000	508,400,000	386,300,000	663,900,000	649,300,000	697,200,000	956,300,000	1,202,600,000	1,383,000,000				1,619,000,000				1,447,000,000				1,088,500,000				1,010,900,000																									412,095,000	416,727,000	384,503,000	381,230,000	358,923,000	373,561,000	278,994,000	262,043,000	249,116,000	243,815,000	237,382,000	230,402,000	212,781,000	199,349,000	192,829,000	181,115,000	178,597,000	171,159,000	143,493,000	140,020,000	138,021,000	8,448,000
total liabilities and stockholders’ equity	1,320,400,000	1,318,600,000	1,461,000,000	1,417,100,000	1,426,100,000	1,477,800,000	1,513,500,000	1,803,600,000	1,823,200,000	1,893,100,000	2,178,800,000	2,949,800,000	3,166,600,000				2,959,000,000				2,883,200,000				2,327,300,000				2,229,400,000																									514,687,000	546,864,000	512,962,000	493,984,000	471,277,000	500,319,000	366,237,000	345,747,000	342,791,000	344,689,000	316,802,000	326,385,000	303,782,000	290,788,000	287,396,000	277,919,000	273,641,000	273,508,000	226,751,000	206,996,000	203,893,000
liabilities and stockholders’ equity
stockholders’ equity:
assets held for sale			6,300,000	6,100,000	6,100,000		33,700,000					225,600,000																																											11,765,000	12,065,000	12,548,000	12,741,000	12,741,000	12,930,000	12,930,000	13,411,000	13,960,000	17,470,000	17,470,000
liabilities held for sale			4,500,000	4,700,000	4,800,000		10,100,000					37,500,000
debt, current portion						800,000	415,200,000	459,200,000	413,700,000	413,600,000	455,200,000	950,700,000	957,300,000	21,200,000	31,600,000	31,600,000	31,600,000	31,600,000	28,800,000	26,000,000	33,800,000	30,900,000	29,100,000	26,300,000	12,900,000	10,100,000	10,100,000
debt, net of current portion						661,800,000	447,000,000	446,700,000	446,500,000	448,200,000	448,000,000	447,700,000	448,500,000	1,032,100,000	793,600,000	801,500,000	809,400,000	817,300,000	825,200,000	833,100,000	841,000,000	848,500,000	758,100,000	762,900,000	798,400,000
goodwill											218,200,000	218,200,000	218,200,000	224,900,000	224,900,000	224,900,000	224,900,000	266,500,000	266,600,000	266,500,000	266,700,000	266,500,000	266,300,000	266,400,000	266,600,000	268,600,000	268,300,000	267,700,000	259,700,000	49,130,000	49,130,000	49,130,000	49,130,000	41,001,000	41,001,000	41,001,000	41,001,000	41,001,000	54,902,000	54,902,000	54,902,000	52,585,000	52,585,000	41,984,000	41,301,000	47,188,000	47,188,000	13,954,000	14,294,000	5,502,000	5,502,000	5,502,000	5,502,000	5,502,000	5,502,000	5,502,000	5,029,000	5,029,000	5,029,000
preferred stock, 0.001 par value...
common stock, 0.001 par value...									100,000			100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	51,000	51,000	50,000	50,000	41,000	41,000	41,000	41,000	41,000	41,000	40,000	40,000	39,000	39,000	38,000	38,000	38,000	38,000	37,000	37,000	36,000	36,000	36,000	36,000	36,000	36,000	36,000	36,000	35,000	35,000	31,000	31,000	31,000		31,000			30,000	30,000	30,000	30,000	30,000	30,000	30,000	28,000
accumulated other comprehensive income									-5,700,000	-2,600,000	-1,600,000	1,000,000	3,100,000
retained earnings									-21,800,000	27,700,000	289,700,000	551,000,000	734,000,000	822,000,000	897,700,000	954,100,000	957,800,000	768,500,000	801,200,000	796,600,000	726,900,000	541,500,000	502,000,000	409,300,000	421,800,000	374,900,000	331,700,000	341,300,000	367,300,000	370,728,000	349,783,000	299,639,000	337,074,000	303,132,000	269,581,000	264,965,000	254,480,000	214,686,000	344,184,000	355,130,000	351,139,000	317,792,000	280,850,000	266,749,000	258,152,000	236,321,000	231,292,000	251,528,000	236,305,000	222,814,000	212,330,000	204,286,000	197,670,000	190,041,000	196,869,000	168,212,000	166,663,000	152,453,000	173,850,000	147,602,000	134,482,000	124,675,000	122,152,000	117,918,000	116,970,000	102,127,000	91,008,000	89,551,000	79,166,000	77,350,000	70,326,000	42,588,000	39,741,000	44,700,000
preferred stock, par value 0.001 per share...
common stock, par value 0.001 per share...										100,000	100,000
total stockholders' equity														1,449,300,000	1,513,200,000	1,575,300,000		1,522,700,000	1,543,700,000	1,522,800,000		1,251,500,000	1,198,800,000	1,074,800,000		1,035,000,000	988,900,000	987,500,000		966,649,000	938,346,000	881,280,000	912,345,000	663,710,000	620,599,000	610,419,000	596,205,000	547,623,000	672,672,000	666,982,000	660,017,000	605,312,000	562,251,000	537,878,000	513,138,000	487,767,000	477,495,000	489,165,000	466,857,000	449,082,000	435,805,000	428,412,000	422,522,000
total liabilities and stockholders' equity														2,908,500,000	2,735,400,000	2,780,400,000		2,867,500,000	2,915,200,000	2,900,100,000		2,616,300,000	2,466,100,000	2,278,700,000		2,333,800,000	2,321,300,000	2,153,700,000		1,173,623,000	1,138,891,000	1,068,467,000	1,070,206,000	1,024,202,000	970,483,000	951,639,000	970,111,000	932,026,000	1,056,466,000	1,035,897,000	1,043,592,000	976,548,000	943,323,000	917,845,000	869,291,000	837,249,000	823,251,000	626,630,000	595,464,000	555,614,000	538,385,000	540,025,000	527,140,000
contingent consideration, net of current portion																4,400,000	4,500,000	5,100,000	5,000,000	5,300,000	34,200,000	35,200,000	6,900,000	26,100,000	26,000,000				54,400,000	9,003,000	9,839,000	10,133,000	9,902,000	9,398,000	9,503,000	9,601,000	9,919,000	20,169,000	22,580,000	23,114,000	23,046,000	22,271,000	33,795,000	41,594,000
contract liabilities, net of current portion																5,900,000	4,700,000	45,300,000	48,900,000	52,500,000	55,500,000	60,400,000	85,300,000	85,000,000	85,600,000
in-process research and development																							29,000,000	29,000,000	29,000,000	41,000,000	41,000,000	41,000,000	50,000,000										41,800,000	42,501,000	42,501,000	42,501,000	52,328,000	77,800,000	50,300,000	50,300,000	50,300,000	41,800,000	41,800,000	41,800,000	41,800,000	41,800,000	41,800,000	41,800,000	51,400,000	51,400,000	51,400,000	51,400,000	51,400,000
contract liabilities, current portion																							32,700,000
contingent consideration, current portion																							22,300,000		3,200,000	55,700,000	54,600,000	62,700,000	5,600,000	2,954,000	2,852,000	2,337,000	2,372,000	2,393,000	1,710,000	2,216,000	3,266,000	2,759,000	2,983,000	2,580,000	2,553,000	2,490,000	3,040,000	6,860,000
income tax receivable																								10,200,000	4,600,000				8,600,000			7,044,000	2,432,000		6,119,000	6,771,000	9,996,000	11,831,000	9,184,000	3,771,000	6,573,000	3,433,000	13,142,000	17,023,000	8,262,000	16,674,000	17,800,000	5,651,000	588,000	6,502,000	10,762,000	9,618,000	10,422,000	19,798,000	9,506,000	24,488,000	17,136,000	23,966,000	8,728,000	13,206,000	8,788,000	5,033,000	2,574,000
deferred tax assets																								17,600,000	13,400,000				13,400,000	12,652,000	12,654,000	12,656,000	2,834,000	4,864,000	5,022,000	5,022,000	6,096,000	11,286,000	18,192,000	11,124,000							1,203,000		1,264,000	1,264,000	1,264,000	327,000	638,000	441,000	1,735,000	7,209,000	7,082,000	6,743,000	2,638,000	2,239,000	2,637,000	2,147,000	1,870,000	7,081,000	10,951,000	11,245,000	12,073,000	12,598,000	12,962,000	11,811,000
contingent consideration																										14,500,000	10,400,000	10,000,000
contract liabilities																										81,600,000
commitments and contingencies
long-term indebtedness, current portion																												10,100,000	10,100,000																				4,470,000	4,470,000	4,470,000	4,148,000	4,057,000	3,280,000	5,360,000	4,920,000	10,229,000	16,927,000	17,187,000	12,038,000	12,186,000	5,797,000	5,791,000	19,087,000	19,308,000	6,316,000	6,248,000	3,739,000	3,707,000	3,524,000	3,514,000	3,485,000	2,597,000	2,638,000
long-term indebtedness																												732,400,000		13,495,000	13,482,000	13,469,000	13,457,000	248,994,000	248,693,000	248,394,000	248,094,000	247,793,000	247,393,000	247,192,000	253,000,000	253,000,000	253,000,000	251,000,000	251,000,000		251,000,000
deferred revenue, net of current portion																												64,700,000	62,500,000	65,343,000	63,255,000	59,365,000	17,259,000	24,966,000	17,092,000	13,887,000	8,433,000	4,695,000	8,410,000	6,817,000	6,590,000	5,987,000	6,083,000	5,806,000	5,815,000	1,632,000	1,805,000									2,781,000	2,953,000	3,823,000	4,386,000									1,853,000	2,180,000	2,325,000	2,473,000	2,685,000	2,773,000	2,859,000
accrued expenses and other current liabilities																													30,700,000	7,425,000	10,552,000	6,840,000	4,831,000	3,918,000	1,874,000	4,346,000	6,368,000	4,279,000	2,482,000	4,187,000	6,229,000	4,214,000	6,442,000	4,606,000	4,688,000	2,957,000	4,879,000	1,252,000	1,359,000	1,067,000	1,517,000	1,332,000	1,623,000	1,134,000	1,170,000	1,150,000	1,200,000	1,257,000	1,309,000	1,300,000	1,137,000	1,575,000	1,570,000	1,320,000	1,162,000	1,175,000	1,399,000	1,463,000	1,267,000	1,499,000	4,056,000	4,055,000	3,537,000	2,907,000
income taxes payable																													4,500,000	164,000	2,771,000			1,875,000																															9,170,000	5,550,000	951,000	2,898,000	4,108,000	3,880,000	7,665,000
deferred revenue, current portion																													10,600,000	10,790,000	9,750,000	6,964,000	13,232,000	4,509,000	15,412,000	10,647,000	7,036,000	4,824,000	7,129,000	9,589,000	7,942,000	8,734,000	7,343,000	5,266,000	5,813,000	5,333,000	5,180,000								1,362,000	4,359,000	5,336,000	5,916,000	7,839,000							227,000	232,000	820,000	901,000	900,000	902,000	729,000	976,000	1,090,000
long-term indebtedness, net of current portion																													784,500,000																	251,000,000		62,000,000	54,952,000	56,069,000	57,187,000	58,866,000	58,140,000	57,592,000	54,094,000	48,873,000	29,074,000	29,657,000	30,239,000	36,225,000	36,910,000	44,165,000	44,927,000	20,500,000	21,250,000	35,208,000	35,935,000	39,651,000	40,605,000	41,702,000	42,588,000	43,488,000	30,020,000	30,746,000
income taxes payable, net of current																																12,500,000	12,500,000
notes payable																																					20,000,000	20,000,000
current assets of discontinued operations
non-current assets of discontinued operations
current liabilities of discontinued operations
non-current liabilities of discontinued operations
provisions for chargebacks																																							2,512,000	1,960,000	2,238,000	1,950,000	1,993,000	2,164,000	2,139,000	4,224,000	4,099,000
deferred tax assets, current portion																																										1,483,000	1,483,000	1,656,000
deferred tax assets, long-term portion																																									11,286,000	13,747,000	13,481,000	12,863,000
deferred tax assets-long-term																																													17,043,000
contingent purchase consideration, current portion																																													2,488,000	3,813,000	3,193,000	1,341,000	1,326,000
deferred tax liability-current portion																																													88,000	88,000
contingent purchase consideration, net of current portion																																													16,745,000	19,193,000	19,127,000	15,278,000	15,255,000
deferred tax liability-long-term
total emergent biosolutions inc. stockholders' equity																																													513,138,000	487,767,000	477,495,000	489,618,000	467,306,000	449,530,000	435,588,000	427,044,000	419,688,000	409,594,000	414,246,000	381,292,000	377,248,000	354,052,000	369,464,000	276,292,000	260,221,000	247,088,000	241,199,000		228,852,000	212,095,000
noncontrolling interest in subsidiaries																																																-453,000	-449,000	-448,000	217,000	1,368,000	2,834,000	2,501,000	2,481,000	3,211,000	3,982,000	4,871,000
deferred tax assets- long-term																																														16,411,000
deferred tax liability long-term
income tax receivable, long-term																																															15,596,000
deferred tax liability, current portion																																															88,000
income tax payable
investments																																																							1,966,000	3,499,000	5,048,000	6,338,000	2,029,000
contingent value rights, current portion																																																							1,748,000	9,865,000	9,734,000	9,113,000
contingent value rights, net of current portion																																																							3,005,000	5,992,000	6,206,000	6,000,000
note receivable																																																												10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
indebtedness under line of credit																																																														15,000,000	15,000,000		15,000,000	15,000,000	15,000,000	15,000,000	15,000,000
contingent value rights																																																											14,532,000
noncontrolling interest in subsidiary																																																											4,097,000	2,702,000	1,822,000	2,028,000	2,616,000	2,000,000	1,550,000	686,000
deferred tax liabilities																																																																1,246,000	262,000	466,000	557,000	597,000	139,000	123,000	211,000
0 shares issued and outstanding at december 31, 2009 and 2008, respectively
30,831,360 and 30,159,546 shares issued and outstanding at
december 31, 2009 and 2008, respectively																																																															31,000
income taxes receivable																																																																1,510,000								12,986,000	14,787,000	3,255,000
total emergent biosolutions inc. stockholders’ equity																																																																235,382,000
shares issued and outstanding at june 30, 2009 and december 31, 2008, respectively
30,319,896 and 30,159,546 shares issued and outstanding at june 30, 2009 and december 31, 2008, respectively																																																																	30,000
shares issued and outstanding at march 31, 2009 and december 31, 2008, respectively
30,241,241 and 30,159,546 shares issued and outstanding at march 31, 2009 and december 31, 2008, respectively																																																																		30,000
preferred stock 0.001 par value...
notes receivable																																																																						3,500,000
indebtedness under lines of credit																																																																						15,000,000	11,832,000
deferred tax assets, net of current																																																																							12,397,000	9,305,000	9,378,000	11,074,000
notes payable to employees
balance sheet data:
working capital																																																																											-3,147,000
total long-term liabilities																																																																											1,228,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31

operating activities
net income	6,800,000	-54,600,000	51,200,000	-12,000,000	68,000,000			9,000,000					-88,000,000	-75,700,000	-56,400,000	-3,700,000	189,300,000	-32,700,000	4,600,000	69,700,000	185,400,000	39,500,000			46,900,000	43,200,000			-3,481,000	20,945,000	50,144,000	-4,908,000	33,942,000	33,551,000	4,616,000	10,485,000	37,392,000			3,991,000	33,347,000			-21,520,000	21,832,000	5,029,000	-20,236,000	15,217,000	13,491,000	10,356,000	-8,805,000	5,620,000			26,900,000	-137,000	12,523,000	-23,173,000	23,888,000	11,944,000	9,434,000	1,918,000	3,661,000	-539,000	13,251,000	10,172,000	1,455,000	10,386,000	1,817,000	7,024,000	2,845,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	1,900,000									4,000,000	8,300,000	6,800,000									10,000,000	10,000,000								4,955,000	4,454,000	7,255,000	3,408,000	3,787,000	3,734,000	4,284,000	3,950,000	4,582,000	4,748,000	5,197,000	4,046,000	4,012,000	3,992,000	3,798,000	3,439,000	3,365,000	2,650,000	2,779,000	2,741,000	2,742,000	2,976,000	2,992,000	2,713,000	2,712,000	2,828,000	2,761,000	2,709,000	2,441,000	1,857,000	1,843,000	1,841,000	1,522,000	1,362,000	1,395,000	1,390,000	860,000	777,000	747,000	756,000	230,000	735,000	631,000	529,000
depreciation and amortization	23,500,000	23,500,000	23,400,000	23,500,000	25,400,000	26,400,000	28,500,000	27,900,000	29,600,000	28,000,000	32,900,000	34,600,000	35,600,000	32,300,000	44,500,000	30,900,000	29,200,000	32,700,000	33,200,000	28,700,000	28,900,000	28,800,000	28,600,000	28,200,000	27,900,000	27,700,000	28,500,000	26,600,000	25,094,000	12,393,000	12,340,000	12,373,000	12,673,000	9,802,000	9,931,000	10,166,000	10,074,000	10,385,000	8,930,000	8,840,000	9,476,000	8,561,000	8,766,000	8,532,000	8,992,000	8,459,000	6,835,000	5,411,000	5,175,000	4,209,000	4,163,000	2,770,000	2,536,000	2,373,000	2,429,000	2,412,000	2,279,000	2,235,000	1,970,000	1,374,000	1,350,000	1,296,000	1,322,000	1,170,000	1,245,000	1,262,000	1,417,000	1,285,000	1,181,000	1,081,000	1,265,000	1,134,000	1,198,000
amortization of deferred financing costs	1,800,000	2,600,000	2,500,000	2,400,000	2,300,000	-6,700,000	5,000,000	6,900,000	5,700,000	5,700,000	8,900,000	1,000,000	1,000,000	1,100,000	1,000,000	1,000,000	1,000,000	1,100,000	1,000,000	1,000,000	1,100,000	900,000	800,000	700,000	800,000	700,000	800,000	700,000
deferred income taxes	-4,500,000	1,500,000	-10,200,000	-13,900,000	18,600,000	7,300,000	-200,000	-12,200,000	-5,200,000	6,500,000	-1,800,000	-8,400,000	-42,000,000	20,400,000	700,000	1,900,000	46,300,000	3,800,000	-1,500,000	-1,700,000	2,000,000	-700,000	500,000	-4,200,000	4,600,000	-4,400,000	10,100,000	-11,400,000																		2,853,000	-8,052,000					4,599,000	-2,864,000	6,944,000	8,251,000	8,808,000	250,000	2,879,000	6,413,000	1,079,000	2,618,000	819,000	368,000	5,896,000	407,000	933,000	1,821,000	822,000	-1,135,000	498,000	121,000	6,897,000	2,400,000
noncash loss on assets held for sale				0	12,200,000
change in fair value of warrant liability	-8,400,000	7,300,000	4,800,000	2,900,000	-9,500,000
loss on disposal of assets	800,000	1,000,000	2,200,000	1,000,000	300,000
other	-3,900,000	9,100,000	400,000	2,200,000	-11,300,000	-11,600,000	18,600,000	-3,100,000	4,100,000	-600,000	9,200,000	300,000	-6,600,000	10,800,000	1,600,000	600,000	-3,100,000	3,100,000	-1,500,000	3,500,000	-5,800,000	-500,000			-900,000	-2,200,000	3,000,000	-100,000	-415,000	549,000	864,000	102,000	308,000	239,000	377,000	87,000	-2,015,000	1,692,000	704,000	71,000	74,000	44,000	136,000	17,000	42,000	46,000	453,000	70,000	-9,000	-16,000	6,000	16,000	-36,000	-19,000	332,000	17,000
changes in operating assets and liabilities:
accounts receivable	-38,900,000	51,900,000	-71,600,000	118,500,000	-73,300,000	82,300,000	20,400,000	-50,000,000	36,900,000	72,100,000	-132,400,000	1,800,000	38,500,000	-21,500,000	4,000,000	93,700,000	66,500,000	-80,000,000	-76,800,000	42,100,000	-25,600,000	62,500,000	-96,100,000	108,200,000	10,400,000	-63,200,000	-97,000,000	141,600,000	-160,655,000	112,706,000	-68,076,000	21,825,000	-14,221,000	-26,749,000	25,599,000	10,561,000	-67,481,000	-8,898,000	2,726,000	51,207,000	-66,100,000	42,633,000	-35,659,000	-5,225,000	33,832,000	-15,316,000	17,590,000	-30,494,000	24,276,000	8,595,000	33,079,000	29,668,000	-3,163,000	30,501,000	-25,205,000	-1,731,000	-35,287,000	27,350,000	-27,841,000	37,828,000	-12,360,000	21,467,000	-29,159,000	29,686,000	18,737,000	-49,281,000	-10,785,000	8,381,000	-933,000	-2,701,000	-22,616,000	-15,462,000	39,396,000
inventories	15,800,000	14,200,000	-17,600,000	-24,700,000	-2,200,000	-18,000,000	-13,000,000	-4,500,000	25,600,000	-1,200,000	5,800,000	-29,600,000	60,300,000	-36,700,000	-25,400,000	-50,100,000	14,000,000	21,700,000	20,200,000	-99,900,000	-35,600,000	-33,900,000	11,900,000	-25,600,000	7,700,000	1,700,000	-20,900,000	-5,200,000	-18,967,000	13,628,000	15,823,000	-12,384,000	953,000	1,640,000	203,000	3,270,000	7,157,000	3,555,000	-8,474,000	-11,264,000	3,134,000	4,638,000	-2,574,000	-16,460,000	3,497,000	5,238,000	-4,006,000	1,682,000	2,257,000	3,566,000	-6,987,000	-2,237,000	1,311,000	-2,658,000	3,318,000	-717,000	4,901,000	-9,441,000	4,598,000	-204,000	-35,000	-3,560,000	2,295,000	-1,774,000	110,000	5,576,000	-2,212,000	1,363,000	-89,000	-1,893,000	3,263,000	-2,001,000	-2,163,000
prepaid expenses and other assets	-500,000	-15,400,000	-2,100,000	19,700,000	9,500,000	-13,700,000	166,000,000	-6,000,000	30,000,000	-500,000	-13,300,000	-4,500,000	9,300,000	-9,800,000	-2,800,000	-16,600,000	30,100,000	-52,400,000	7,600,000	-10,000,000	32,600,000	-44,900,000	-1,600,000	-15,300,000	9,100,000	8,400,000	-28,300,000	-16,600,000	-1,979,000	199,000	1,485,000	-7,605,000	-1,573,000	-2,433,000	-2,062,000	2,338,000	1,057,000	-1,433,000	3,842,000	-5,555,000	1,309,000	-1,455,000	2,714,000	-249,000	-10,278,000	-1,123,000	556,000	-2,694,000	-1,798,000	-1,488,000	-246,000	-2,432,000	445,000	443,000	390,000	-1,287,000	549,000	1,008,000	141,000	-953,000	-417,000	576,000	-1,443,000	-2,158,000	-8,000	2,379,000	-797,000	-943,000	-1,401,000	-405,000	-86,000	-731,000	-292,000
accounts payable	-14,400,000	11,400,000	-4,000,000	-10,400,000	-5,400,000	-23,000,000	2,600,000	-2,400,000	-7,100,000	6,800,000	-20,100,000	31,000,000	-5,000,000	-1,400,000	7,100,000	-14,700,000	-6,000,000	-4,500,000	-12,100,000	20,100,000	9,200,000	25,100,000	1,100,000	-15,600,000	14,000,000	-40,100,000	38,400,000	4,200,000	-1,305,000	-1,301,000	-7,970,000	3,576,000	13,169,000	-1,280,000	4,164,000	81,000	-13,486,000	-12,592,000	10,902,000	385,000	2,847,000	-160,000	960,000	1,102,000	-819,000	356,000	-10,713,000	1,071,000	4,577,000	-2,003,000	-4,196,000	3,573,000	-5,080,000	-1,988,000	2,391,000	885,000	-313,000	-453,000	-2,367,000	1,839,000	3,036,000	1,115,000	-5,706,000	5,521,000	-960,000	-189,000	708,000	-3,158,000	3,750,000	-1,757,000	2,722,000	-675,000	-2,735,000
accrued expenses and other liabilities	-1,800,000	16,800,000	1,300,000	-21,100,000	-7,200,000	29,100,000	2,700,000	1,100,000	-25,500,000	-16,400,000	900,000	-14,700,000	31,300,000	-15,200,000	-26,300,000	-56,500,000	10,100,000	36,100,000	-15,400,000	-40,000,000									-14,057,000	-3,150,000	3,367,000	2,240,000	3,960,000	2,052,000	-2,424,000	-1,962,000	2,323,000	1,834,000	-1,488,000	-2,045,000	2,105,000	-2,217,000	1,798,000	-1,641,000	1,670,000	-2,190,000	1,546,000	247,000	379,000	-640,000	21,000	-187,000	499,000	-11,000	64,000	-185,000	20,000	6,000	133,000	-27,000	-475,000	146,000	-117,000	-52,000	223,000	-120,000	-1,399,000	1,365,000	-219,000	-270,000	171,000	749,000	-223,000
long-term incentive plan accrual	400,000	800,000	700,000	800,000	800,000	600,000	700,000	1,200,000
accrued compensation	-20,200,000	4,500,000	4,500,000	5,900,000	-32,200,000	-2,900,000	26,300,000	-33,300,000	-9,600,000	12,600,000	11,900,000	-25,300,000	5,800,000	8,400,000	18,100,000	-32,200,000	15,100,000	10,300,000	8,000,000	-29,400,000	7,300,000	17,900,000	11,500,000	-14,900,000	6,600,000	11,100,000	7,800,000	-21,300,000	4,475,000	12,546,000	4,744,000	-13,365,000	5,251,000	8,292,000	1,009,000	-11,203,000	2,388,000	4,814,000	3,311,000	-8,277,000	4,368,000	3,785,000	5,410,000	-10,883,000	3,694,000	4,818,000	-8,720,000	6,256,000	2,966,000	3,852,000	-10,982,000	2,110,000	3,995,000	-10,895,000	5,937,000	912,000	136,000	-10,288,000	7,384,000	2,169,000	2,234,000	-5,580,000	763,000	4,201,000	1,676,000	-3,094,000	2,325,000	1,740,000	723,000	-2,910,000	6,000	2,887,000	-2,467,000
income taxes receivable and payable	4,600,000	-6,300,000	6,200,000	6,800,000	-8,400,000	10,500,000	0	16,100,000	-12,700,000	-17,700,000	1,300,000	12,900,000
contract liabilities	3,200,000	4,100,000	1,200,000	200,000	-300,000	700,000	200,000	-19,700,000	4,100,000	9,500,000	700,000	-8,400,000	5,400,000	1,500,000	4,700,000	-2,000,000	-12,300,000	-19,900,000	-9,000,000	9,400,000	20,200,000	-38,100,000	28,600,000	500,000
net cash from operating activities	-33,800,000	77,700,000	-2,300,000	106,400,000	-11,200,000	153,700,000	47,500,000	-62,600,000	32,100,000	60,000,000	-114,400,000	-184,000,000	92,800,000	-74,000,000	-15,600,000	-37,300,000	329,000,000	16,700,000	-29,700,000	5,100,000	245,100,000	105,200,000	127,900,000	57,800,000	122,100,000	-3,100,000	-35,800,000	104,800,000	-165,764,000	173,973,000	34,582,000	-991,000	78,951,000	33,515,000	54,002,000	41,671,000	-9,174,000	26,978,000	-2,112,000	37,795,000	3,070,000	104,759,000	2,503,000	-65,873,000	78,923,000			8,641,000	60,125,000	32,828,000	-4,626,000	46,897,000	18,912,000	15,820,000	38,564,000	4,836,000	-6,752,000	-22,055,000	24,178,000	54,172,000	3,792,000	17,401,000	-23,287,000	33,336,000	45,908,000	-25,446,000	-11,939,000	19,943,000	4,341,000	-5,028,000	-10,108,000	-28,373,000	14,786,000
capital expenditures	-1,400,000	-4,100,000	-3,800,000	-2,200,000	-2,100,000	-7,100,000	-5,000,000	-7,500,000	-14,900,000	-11,100,000	-12,600,000	-7,300,000	-24,200,000	-25,200,000	-38,100,000	-18,900,000	-47,300,000	-66,300,000	-800,000	-23,600,000	-36,000,000	-52,800,000	-25,600,000	-16,900,000	-36,100,000	-15,300,000	-14,100,000	-21,400,000	0	-26,058,000	-13,602,000	-11,615,000	0	0	-9,301,000	-20,304,000	-20,014,000	-16,997,000	-21,032,000	-18,214,000	-11,181,000	-13,950,000	-10,599,000	-9,082,000	-5,221,000			-7,601,000	-20,297,000	-6,444,000	-7,679,000	-10,022,000	-8,592,000	-22,329,000	-19,873,000	-17,358,000	-8,363,000	-8,432,000	-8,059,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-5,612,000	-6,294,000	-6,090,000	-11,833,000	-10,979,000
free cash flows	-35,200,000	73,600,000	-6,100,000	104,200,000	-13,300,000	146,600,000	42,500,000	-70,100,000	17,200,000	48,900,000	-127,000,000	-191,300,000	68,600,000	-99,200,000	-53,700,000	-56,200,000	281,700,000	-49,600,000	-30,500,000	-18,500,000	209,100,000	52,400,000	102,300,000	40,900,000	86,000,000	-18,400,000	-49,900,000	83,400,000	-165,764,000	147,915,000	20,980,000	-12,606,000	78,951,000	33,515,000	44,701,000	21,367,000	-29,188,000	9,981,000	-23,144,000	19,581,000	-8,111,000	90,809,000	-8,096,000	-74,955,000	73,702,000			1,040,000	39,828,000	26,384,000	-12,305,000	36,875,000	10,320,000	-6,509,000	18,691,000	-12,522,000	-15,115,000	-30,487,000	16,119,000	48,761,000	191,000	12,371,000	-42,198,000	28,054,000	41,569,000	-30,201,000	-16,288,000	16,022,000	-1,271,000	-11,322,000	-16,198,000	-40,206,000	3,807,000
investing activities
purchases of property, plant and equipment	-2,400,000	-3,900,000	-3,400,000	-2,900,000	-3,600,000	-5,800,000	-4,600,000	-10,800,000	-11,400,000	-12,600,000	-12,500,000	-15,100,000	-23,600,000	-27,900,000	-32,100,000	-32,200,000	-46,700,000	-55,200,000																	-9,301,000	-20,304,000	-20,014,000	-16,997,000	-21,032,000	-18,214,000	-11,181,000	-13,950,000	-10,599,000	-9,082,000	-5,221,000	-4,810,000	-4,590,000	-7,601,000	-20,297,000	-6,444,000	-7,679,000	-10,022,000	-8,592,000	-22,329,000	-19,873,000	-17,358,000	-8,363,000	-8,432,000	-8,059,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-5,612,000	-6,931,000	-8,854,000	-10,853,000	-16,490,000
proceeds from sale of property, plant and equipment		0	0	100,000	38,100,000
milestone payments from prior asset divestiture		0	0	20,000,000	30,000,000
purchase of convertible note receivable		0	0	0	-5,000,000
net cash from investing activities	-2,400,000	-3,900,000	-3,400,000	17,200,000	59,500,000	112,000,000	-4,600,000	-10,800,000	-11,400,000	-18,900,000	257,700,000	-15,100,000																	-848,549,000	-26,058,000	-10,978,000	-11,615,000	-207,551,000	-12,776,000	-9,301,000	-20,304,000	-20,014,000	-16,997,000	-21,032,000	-18,214,000	-11,831,000	-13,950,000	-10,599,000	-9,082,000	-5,221,000	-4,810,000	-182,757,000	-9,354,000	-44,417,000	-6,444,000	-7,679,000	-10,022,000	-8,592,000	-8,598,000	-18,340,000	-15,809,000	-7,073,000	-12,741,000	-9,414,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-12,112,000	-10,431,000	-13,854,000	-10,853,000	-16,490,000
financing activities
proceeds from issuance of common stock upon exercise of stock options	400,000	1,200,000																						9,100,000
purchases of treasury stock	-9,000,000	-9,100,000	-8,900,000										-200,000	0	-24,400,000	-57,500,000
proceeds from stock-based compensation activity									500,000	0
taxes paid for stock-based compensation activity	-2,800,000								-100,000	-100,000	-200,000	-2,100,000
net cash from financing activities:	-11,400,000	-113,900,000	-15,900,000	-6,400,000	-400,000	-180,300,000	-50,900,000	40,700,000	4,700,000	-43,000,000	-486,900,000	-10,500,000	353,100,000	229,300,000	-30,700,000	-70,500,000	-110,000,000	-5,000,000	-3,800,000	-22,200,000		87,100,000	4,700,000	-20,000,000		-19,700,000	100,100,000	-58,400,000
effect of exchange rate changes on cash, cash equivalents and restricted cash		0	-200,000	1,000,000	-700,000				-1,500,000	1,100,000	-600,000	-200,000	1,100,000	-1,000,000	700,000	-300,000	0	-200,000	200,000	-300,000		-400,000	-200,000	100,000						-471,000	-141,000	45,000
net change in cash, cash equivalents and restricted cash	-47,600,000	-40,100,000	-21,800,000	118,200,000	47,200,000	85,400,000	-8,000,000	-32,700,000	23,900,000	-800,000			401,600,000	-117,300,000	-77,700,000	-140,300,000	172,300,000	-43,700,000	-100,300,000	-73,500,000
cash, cash equivalents and restricted cash, beginning of period	209,100,000	0	0	0	105,600,000	0	0	111,700,000	0	0	0	642,600,000
cash, cash equivalents and restricted cash, end of period	161,500,000	-40,100,000	-21,800,000	118,200,000	152,800,000	85,400,000	-8,000,000	79,000,000	23,900,000	-800,000	-341,600,000	430,200,000
supplemental cash flow disclosures:
cash paid for interest	13,100,000	8,000,000	16,900,000	8,100,000	16,700,000	19,800,000	14,500,000	21,500,000	11,800,000	17,700,000	17,200,000	21,600,000
cash paid for income taxes, net of refunds	5,300,000	12,500,000	10,900,000	2,100,000	14,500,000
non-cash investing and financing activities:
purchases of property, plant and equipment unpaid at period end	1,000,000	-200,000	-400,000	700,000	1,500,000	-1,300,000	-400,000	3,300,000	-3,500,000	1,500,000	-100,000	7,800,000	-600,000	2,700,000	-6,000,000	13,300,000	-600,000	-11,100,000	-800,000	32,500,000		-7,100,000	9,500,000	7,300,000																																														637,000	2,764,000	-980,000	5,511,000
excise tax liability accrued for treasury stock purchases	100,000
reconciliation of cash and cash equivalents and restricted cash:
cash and cash equivalents	160,300,000	-40,100,000	-21,800,000	118,200,000	149,100,000	80,200,000	-8,800,000	78,500,000				430,200,000	401,700,000	-117,200,000	-77,700,000	435,800,000	172,300,000	-43,700,000	-100,300,000	547,800,000	206,300,000	146,200,000	87,300,000	181,500,000
restricted cash	1,200,000	0	0	0	3,700,000	5,200,000	800,000	500,000						-100,000	0	200,000	0	0	0	200,000	0	0	0	200,000									0
total	161,500,000	-40,100,000	-21,800,000	118,200,000	152,800,000	85,400,000	-8,000,000	79,000,000				432,800,000	401,600,000	-117,300,000	-77,700,000	436,000,000	172,300,000	-43,700,000	-100,300,000	548,000,000	206,300,000	146,200,000	87,300,000	181,700,000
share-based compensation expense		5,300,000	4,800,000	4,600,000	1,500,000	2,300,000	5,500,000	5,900,000						11,200,000	12,300,000	9,900,000		10,400,000	11,400,000	10,500,000				6,600,000		6,100,000	8,100,000	6,800,000
change in fair value of contingent obligations						0	100,000	500,000	600,000	-2,300,000	400,000	1,500,000																							233,000	200,000	-9,585,000	-2,188,000	88,000	847,000	299,000	-11,649,000				1,218,000	412,000
noncash gain on sale of business
goodwill impairment									0
impairment of long-lived assets						0			0	0																					229,000	34,000																							300,000	483,000
proceeds from sale of business
proceeds from the issuance of debt, net of lender fees
proceeds allocated to warrants issued in conjunction with debt
proceeds allocated to common stock issued in conjunction with debt
principal payments on term loan facility						-190,300,000	-4,000,000	-3,900,000	-3,900,000	-3,900,000	-148,400,000	-8,400,000	-8,500,000	-8,400,000	-8,400,000	-8,500,000	-8,400,000	-5,600,000	-5,700,000	-5,600,000	-5,700,000	-2,800,000	-2,800,000	-2,800,000	-2,900,000	-2,800,000	-2,800,000	-2,800,000
proceeds from revolving credit facility						0	15,000,000	50,000,000					360,000,000												0	0	100,000,000	30,000,000
principal payments on revolving credit facility						-222,700,000	-56,500,000	-5,000,000	-12,000,000	-39,000,000											0	-353,000,000	0	-20,000,000	-10,000,000	-15,000,000	0	-80,000,000
debt issuance costs						-8,700,000															0												0
repurchase of debt		-1,800,000
prepayment premium on debt principal payment
proceeds from share-based compensation activity				700,000	100,000	0								0	2,500,000	500,000		2,500,000	3,100,000	6,900,000
proceeds from at-the-market sale of stock, net of commissions and expenses									200,000	0
taxes paid for share-based compensation activity		-400,000	-300,000	-200,000	-500,000	-300,000	-200,000	-400,000						-300,000	-400,000	-5,000,000		-500,000	-800,000	-12,200,000	-1,000,000	-1,100,000
gain on extinguishments of debt
issuance of common stock in conjunction with debt
excise tax liability accrued for common stock repurchases		100,000
loss on sale of business and assets held for sale
gain on extinguishment of debt							0	300,000
change in fair value of warrant and forward liabilities
milestone payment from prior asset acquisition									0													0
cash paid for income taxes						9,600,000	13,500,000	12,400,000	14,500,000	11,400,000	10,200,000	16,700,000
net loss										-266,700,000	-261,300,000	-183,000,000												-12,500,000				-26,000,000																										-8,022,000																			-2,690,000
adjustments to reconcile net loss to net cash from operating activities:
add: net change in cash, classified within current assets held for sale												-2,600,000
gain on sale of travel health business									0	700,000
write off of contract asset and liability
royalty settlement payment
asset acquisitions													0
proceeds from sale of travel health business									0	0
principal payments on convertible senior notes																	0	0	0	-10,600,000
contingent consideration payments																	1,300,000	-1,400,000	-400,000	-700,000	-600,000	-1,100,000	-400,000	-700,000	-46,700,000	-2,700,000	-500,000	-500,000	-1,166,000	-977,000	-464,000	-793,000	-8,197,000
purchases of treasury stock unpaid at period end
long-term incentive plan expense										1,300,000
supplemental disclosure of cash flow information:
supplemental information on non-cash investing and financing activities:
net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale												-209,800,000
reconciliation of cash and cash equivalents and restricted cash at march 31, 2023 and december 31, 2022:
cash and cash equivalents included in assets held for sale												2,600,000
impairments
proceeds from senior unsecured notes																					0
cash flows from operating activities:
adjustment for prior period lease receivables
change in fair value of contingent consideration														600,000	1,300,000	500,000		900,000	600,000	1,100,000	400,000	30,200,000	500,000	600,000	12,400,000	6,900,000	3,800,000	1,700,000		243,000	685,000	989,000												1,559,000
cash flows from investing activities:
net cash from investing activities:														-271,600,000	-32,100,000	-32,200,000		-55,200,000	-67,000,000	-56,100,000	-36,000,000	-45,700,000	-45,100,000	-24,200,000	-36,100,000	-15,300,000	-24,100,000	-21,400,000
cash flows from financing activities:
cash, cash equivalents and restricted cash at beginning of period														0	0	576,300,000	0	0	0	621,500,000		0	0	168,000,000		0	0	112,400,000		0	0	179,335,000
cash, cash equivalents and restricted cash at end of period														-117,300,000	-77,700,000	436,000,000	172,300,000	-43,700,000	-100,300,000	548,000,000		146,200,000	87,300,000	181,700,000		-38,200,000	40,200,000	137,400,000		149,121,000	26,631,000	164,649,000
cash paid during the period for interest														11,900,000	3,100,000	11,700,000		11,800,000	3,100,000	12,400,000		2,400,000	4,200,000	7,400,000																																															699,000	874,000	644,000
cash paid during the period for income taxes														3,900,000	15,200,000	4,800,000		7,300,000	48,800,000	1,500,000		75,100,000	8,600,000	3,600,000																																															369,000	1,460,000	12,500,000
reconciliation of cash and cash equivalents and restricted cash at september 30, 2022 and december 31, 2021:
reconciliation of cash and cash equivalents and restricted cash at june 30, 2022 and december 31, 2021:
reconciliation of cash and cash equivalents and restricted cash at march 31, 2022 and december 31, 2021:
cash paid during the year for interest
cash paid during the year for income taxes
impairment of ipr&d
cash flows used in investing activities:
reconciliation of cash and cash equivalent and restricted cash at september 30, 2021 and december 31, 2020:
adjustments to reconcile to net income to net cash from operating activities:
reconciliation of cash and cash equivalent and restricted cash at june 30, 2021 and december 31, 2020:
purchases of property, plant and equipment and other																				-56,100,000	-36,000,000	-45,700,000	-35,100,000	-24,200,000	-36,100,000	-15,300,000	-14,100,000	-21,400,000		-26,058,000	-13,602,000	-11,615,000
reconciliation of cash and cash equivalent and restricted cash at march 31, 2021 and december 31, 2020:
adjustments to reconcile to net cash from operating activities:
impairment of ipr&d intangible asset																					0
milestone payment from asset acquisition																									0
business acquisitions, net of cash acquired
proceeds from sale of assets																													-24,000	0																						0	0	11,765,000
proceeds from term loan facility
receipts and payments of restricted cash
purchase of treasury stock																													45,000	0	0	-145,000	-32,994,000	0	-2,000	-81,000
net cash from financing activities																													785,980,000	1,677,000	3,168,000	-2,125,000	-34,146,000	4,687,000	765,000	-22,707,000	1,779,000	-44,415,000	15,366,000	8,629,000	12,972,000	3,076,000	6,405,000	10,996,000	402,000	1,909,000	192,874,000	7,510,000	647,000	-540,000	995,000	-784,000	1,099,000	-730,000	-2,454,000	14,347,000	-1,037,000	3,395,000	2,963,000	807,000	-14,002,000	874,000	26,692,000	-11,870,000	-166,000	188,000	2,892,000	4,484,000	-700,000	2,292,000	14,411,000	5,872,000	-6,899,000
effect of exchange rate changes on cash and cash equivalents																																	47,000	-62,000	-9,000	-3,000	-10,000	-29,000	157,000	11,000	-134,000	-8,000	17,000	-25,000	15,000	-3,000	5,000	-20,000	-37,000	161,000	-118,000	-33,000	-1,000	32,000	785,000	-122,000	31,000	-693,000	63,000	-532,000	-380,000	215,000	-347,000	85,000	-275,000	-80,000	181,000	175,000	-269,000	184,000	-163,000	-311,000	-170,000
net change in cash and cash equivalents and restricted cash
cash and cash equivalents and restricted cash at beginning of year
cash and cash equivalents and restricted cash at end of year
issuance of common stock to acquire adapt pharma
purchases of property, plant and equipment unpaid at year end
accrued expenses																						-20,600,000	23,900,000	1,100,000		-1,700,000	5,200,000	1,700,000
proceeds from exercise of stock options																						3,500,000
net increase in cash, cash equivalents and restricted cash																						146,200,000	87,300,000	13,700,000		-38,200,000	40,200,000	25,000,000		149,121,000
reconciliation of cash and cash equivalent and restricted cash at september 30, 2020 and december 31, 2019:
reconciliation of cash and cash equivalent and restricted cash at june 30, 2020 and december 31, 2019:
taxes paid on behalf of employees for equity activity																								-5,600,000	-800,000	-300,000	-300,000	-6,000,000	-297,000	-283,000	-140,000	-5,880,000	-76,000	-125,000	-44,000	-4,015,000
reconciliation of cash and cash equivalent and restricted cash at march 31, 2020 and december 31, 2019:
share-based compensation
income taxes																													-17,861,000	4,286,000	12,943,000	-4,468,000	1,449,000	13,667,000	652,000	4,299,000	376,000	4,267,000	-2,417,000	2,964,000	-19,454,000	15,274,000	12,790,000	-12,160,000	737,000	-1,431,000	-3,753,000	-252,000	1,072,000	-81,000	-7,918,000	566,000	8,991,000	-11,154,000	17,182,000	-7,352,000	6,830,000	-15,238,000	4,478,000	-4,418,000	-3,755,000	-2,459,000	-1,064,000	-10,680,000	3,620,000	4,599,000	-1,947,000	-1,210,000	228,000	-3,785,000	1,801,000	-9,935,000	-17,686,000
deferred revenue																											14,300,000	2,100,000	-3,062,000	3,128,000	6,676,000	-6,542,000	1,016,000	-3,029,000	7,970,000	9,065,000	5,950,000	-2,355,000	-867,000	1,874,000	-189,000	1,295,000	2,354,000	14,000	4,662,000	-19,000	-1,227,000	-252,000	40,000	41,000	197,000	70,000	1,217,000	-1,075,000	-5,778,000	-1,149,000	-1,450,000	-2,486,000	-821,000	12,000	0	-14,000	0	-223,000			-2,441,000	-408,000	-144,000	-150,000	-335,000	-199,000	-481,000
payment of notes payable to aptevo
net increase in cash and cash equivalents and restricted cash
cash flows from provided by financing activities:
issuances of stock under share-based benefit plans																										1,100,000	3,700,000	900,000
stock-based compensation
impairment and abandonment of long-lived assets
excess tax benefits from stock-based compensation																																					206,000	-383,000	-4,656,000	-5,786,000	-3,279,000	-761,000	-1,827,000	-5,414,000	-387,000	-609,000	-4,570,000	-1,150,000	-192,000	-149,000	-1,608,000	238,000	385,000	862,000	-698,000	284,000	-1,747,000	-39,000	-623,000	-368,000	-333,000	-376,000	-297,000	-1,042,000	-317,000	-196,000					0
changes in operating assets and liabilities, net of business acquisitions:
proceeds from long-term debt obligations																																									0	0
principal payments on long-term indebtedness																																													0	0	-62,000,000		-1,117,000	-1,118,000	-1,117,000	-716,000	-467,000	-8,203,000
distribution to aptevo
net decrease in cash and cash equivalents																																											-1,674,000	-63,984,000																						-30,093,000		20,681,000	-8,740,000	-12,983,000	-9,714,000	-33,665,000	-8,773,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
income taxes payable
issuance of common stock upon exercise of stock options																														2,937,000	3,772,000	4,693,000	8,547,000	6,194,000	1,648,000	2,957,000	2,144,000	457,000	10,929,000	3,595,000	10,059,000	2,740,000	6,818,000	6,344,000
payments of notes payable to aptevo
net decrease in cash, cash equivalents and restricted cash																																-14,686,000
impairment of intangible assets
bad debt expense
provision for chargebacks																																						-171,000	552,000	-278,000	288,000	-43,000
acquisitions
payments of notes payable																																	0	0	0	-20,000,000
net increase in cash and cash equivalents																																	-162,699,000	25,364,000	45,457,000	-1,343,000	-27,419,000	-34,463,000	-7,621,000	28,221,000	4,077,000				74,119,000	7,915,000	-19,123,000	6,777,000	16,318,000	26,005,000	-11,428,000	36,058,000	11,418,000	6,524,000	18,555,000	3,252,000	-14,831,000	-32,094,000	17,790,000	49,036,000	-14,191,000	13,460,000	-15,853,000	16,269,000
abandonment of long-lived assets
distribution of aptevo
cash and cash equivalents at beginning of period																																		0	0	271,513,000		0	0	312,795,000		0	0	280,499,000	0	0	179,338,000		0	0	141,666,000	0	0	143,901,000		0	0	169,019,000		0	0	102,924,000		0	0	91,473,000		0	0	105,730,000	0	0	76,418,000
cash and cash equivalents at end of period																																		25,364,000	45,457,000	270,170,000		-34,463,000	-7,621,000	341,016,000		93,877,000	-1,674,000	216,515,000	74,119,000	7,915,000	160,215,000		16,318,000	26,005,000	130,238,000	36,058,000	11,418,000	150,425,000		3,252,000	-14,831,000	136,925,000		49,036,000	-14,191,000	116,384,000		16,269,000	41,128,000	61,380,000		20,681,000	-8,740,000	92,747,000	-9,714,000	-33,665,000	67,645,000
contingent obligation payments																																			-837,000	-1,568,000	-159,000	-255,000	-219,000	-752,000	-266,000	-425,000	-4,240,000	-762,000	-672,000	-532,000	-487,000
write off of debt issuance costs																																													0	0	1,831,000
acquisitions, net of acquired cash
proceeds from convertible debenture, net of bank fees
non-cash development expenses from joint venture																																																1,000	-1,000	-537,000	190,000								3,754,000	2,056,000	168,000	17,000	1,189,000	1,938,000	2,455,000	1,633,000
impairment of in-process research and development																																									0											0	0	9,600,000
acquisition of cangene corporation, net of acquired cash																																													0	0	-178,167,000
current and deferred income taxes																																												-7,261,000					4,802,000	4,381,000	-4,516,000
benefit from chargebacks																																												-82,000	-592,000	125,000	159,000
change in fair value of contingent purchase consideration
acquisition of healthcare protective products division																																																-1,753,000
proceeds from convertible debenture, net of debt issuance costs																																													0	0	241,654,000
proceeds from other long-term debt obligations																																													0	0	1,000,000
issuance of common stock subject to equity programs
issuance of common stock subject to exercise of stock options																																														1,832,000	8,137,000				504,000	94,000	159,000	242,000	1,190,000	141,000	4,497,000	4,198,000	3,179,000	1,272,000	1,531,000	1,253,000	271,000	3,059,000	483,000	651,000	2,771,000	406,000			55,000	1,529,000	890,000
net cash used by operating activities																																															-29,245,000
proceeds from maturity of investments																																																				0	0	1,966,000	500,000	1,500,000
purchase of investments																																																							1,033,000	49,000	-960,000	-4,309,000
proceeds from borrowings on long-term indebtedness																																																				1,533,000	1,792,000	9,621,000
principal payments on long-term indebtedness and line of credit																																																							-563,000	-6,808,000	-7,281,000	-842,000	-837,000	-833,000	-15,866,000	-15,755,000	-1,052,000	-15,971,000	-15,966,000	-15,659,000
restricted cash deposit
change in fair value of contingent value rights																																																				0	0	-3,005,000	-1,104,000	-83,000
issuance of common stock subject to employee equity plans																																																	1,572,000
contingent value right payment																																																				0	0	-1,748,000
non-cash development expenses from joint ventures																																																				-469,000	2,420,000	1,212,000				2,550,000
release of restricted cash deposit																																																				0	0	220,000
benefit from impairment of accrued interest on note receivable
acquisition of trubion pharmaceuticals, inc., net of cash acquired
repayment of note receivable
proceeds from borrowings on long-term indebtedness and line of credit																																																							6,224,000							15,000,000				15,000,000
issuance of common stock to acquire trubion pharmaceuticals, inc.
non-cash development expenses from variable interest entities																																																								915,000
proceeds from borrowing on line of credit
gain on disposal of property and equipment																																																										13,000				-34,000					47,000	1,000
benefit from impairment of long-lived assets																																																											189,000	0	481,000	548,000	3,510,000	0
benefit from fair value of contingent value rights																																																										581,000
proceed from maturities of investments
repayment/(issuance) of note receivable
restricted cash release																																																																			-8,000
(gain) loss on disposal of property, plant and equipment
proceeds from borrowings on line of credit																																																												0
(gain) loss on disposal of property and equipment
issuance of note receivable
gain on disposal of property, plant and equipment																																																																-3,000
proceeds from line of credit
loss on disposal of property and equipment																																																																		25,000				10,000
adjustments to reconcile net income to net cash from operating activities
purchased in-process research and development
acquisitions, net of cash received
proceeds from borrowings on long term indebtedness and line of credit																																																																			15,000,000	15,000,000
issuance of common stock in initial public offering
redemption of class b common stock
principal payments on long term indebtedness, notes payable to employees, and line of credit
minority interest in subsidiary
issuance of a note receivable
principal payments on long term indebtedness and line of credit
principal payments on long term indebtedness and line of credits
issuance of notes receivable																																																																						-3,500,000
proceeds from borrowings on long term indebtedness and lines of credit																																																																						15,000,000
principal payments on long term indebtedness, notes payable to employees, and lines of credits																																																																						-12,708,000			-9,386,000
restricted cash deposits
principal payments on long term indebtedness, notes payable to employees, and lines of credit																																																																							-977,000
proceeds from excess tax benefits																																																																									1,597,000
non-cash gain on settlement
other obligations
excess tax benefit from stock based compensation
proceeds from investment maturities
proceeds from notes payable to employees
repayments on product supply and royalty obligations
payment of dividend
issuance of common stock to acquire microscience limited

Emergent BioSolutions Inc(NYSE:EBS)

Emergent BioSolutions Inc
(NYSE:EBS)